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The increasing understanding of the cellular responses to anti-cancer 
drugs has revealed many new and effective opportunities for cancer therapy. 
Safingol, which belongs to the family of sphingolipids, was originally 
developed as a protein kinase C (PKC) and sphingosine kinase (SK) inhibitor, 
and is currently evaluated in Phase I clinical trials. Yet, the underlying 
mechanisms of its action remain largely unknown. The research presented in 
this thesis focused on elucidating the mechanism of safingol and its potential 
to synergize with conventional anti-cancer drugs. 
 
The results presented in Chapter 3 demonstrated that, as a single agent, 
safingol was more potent than irinotecan and 5-fluorouracil (5-FU) in HT-29 
and LS-174T colon cancer cell lines. Furthermore, the combination of 
safingol/irinotecan at 1:1 molar ratio was found to be additive in HT-29 cells 
(CI = 0.94) and synergistic in LS-174T cells (CI = 0.68), and resulted in 
concentration- and time-dependent down-regulation of phosphorylated PKC 
and its downstream substrate, phosphorylated myristoylated alanine-rich C-
kinase substrate (MARCKS). Observations that 1:1 safingol/irinotecan 
combination inhibited the adhesion of colon cancer cells to the extracellular 
matrix further supported the ability of this drug combination to modulate PKC 
downstream signaling. These results suggested that modulation of the PKC 
pathway could be a possible molecular basis for the observed synergism of the 
safingol/irinotecan combination. Intriguingly, the results showed that safingol 
as a single agent, however, did not inhibit PKC at the concentration that 
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caused substantial cell kill. This finding suggested that alternative molecular 
effects could be induced by safingol, and led to the study in Chapter 4.  
 
The results summarized in Chapter 4 are the first to document that 
safingol induced concentration- and time-dependent reactive oxygen species 
(ROS) generation in cancer cells, and ROS appeared to be a critical mediator 
in safingol-induced necrosis. Depending on the levels of ROS generated, two 
opposite cellular responses were observed. Low levels of ROS generation 
triggered autophagy which serves as a catabolic process to remove damaged 
organelles. When the oxidative stress levels were high, cells died by necrosis. 
In addition, the current results suggested that Bcl-xL and Bax are involved in 
the regulation of safingol-induced autophagy, despite their well-established 
roles in regulating apoptosis. Furthermore, the results in Chapter 4 suggested 
that safingol inhibited glucose uptake and activated AMP-activated protein 
kinase (AMPK) prior to ROS generation.  
 
By elucidating the molecular effects of safingol, anti-cancer drug 
combinations based on safingol could be appropriately identified for effective 
treatment. The aim of Chapter 5 was to evaluate the activity of safingol in 
combination with various apoptotic- and ROS-generating chemotherapeutic 
agents using a variety of cancer cell lines. Safingol was able to synergize with 
carboplatin, doxorubicin, gemcitabine and vincristine over a range of the fixed 
molar drug ratios tested. In addition, the results in Chapter 5 supported the 
notion that ROS was an important factor in mediating the observed synergism. 
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The use of safingol-based drug combinations holds therapeutic promise as an 
effective strategy for cancer therapy, and warrants future in vivo studies. 
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Chapter 1. Introduction  
 
 
1.1. Overview of Cancer  
 
Cancer is one of the modern plagues of the world today. In general, 
cancer is characterized as uncontrolled growth and spread of abnormal cells. 
In 2000, Hanahan and Weinberg described six important phenotypic 
differences between healthy and cancerous cells (Figure 1.1). These include 
insensitivity to anti-growth signals, tissue invasion and metastasis, limitless 
replicative potential, sustained angiogenesis, evading apoptosis and self 
sufficiency in growth signals (1). However, it is becoming increasingly clear 
that these hallmarks do not portray the whole story of cancer. Recently, 
Colotta et al has proposed cancer-related inflammation as the seventh 
hallmarks of cancer (2). Similarly, accumulating evidence now suggests that a 
shift in cellular metabolism might be added to the list (3). In short, cancer is a 
complex disease of multiple aberrations in the biological processes of the cell.  
 
According to World Cancer Report 2003 by World Health 
Organization (WHO), global cancer rates could increase by 50% from 10 
million new cases in 2000 to 15 million new cases in 2020 (4). Furthermore, 
based on the rate estimated from 2002-2004, the National Cancer Institute 
(NCI) of the USA reported that 40.93% of men and women born today will be 




Figure 1.1 Hallmarks of cancer. Adapted from Reference (1-3)  
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 As a cause of death in Singapore, cancer has continued to increase in 
importance over the last three decades. It is estimated that a total of 43,424 
incidents of cancer are diagnosed across Singapore from 2002 to 2006 and 
approximately 1 in 4 Singaporeans will lose their lives to this disease (5). 
Table 1.1 lists the top ten most prevalent types of cancer occurring in 
Singaporean men and women (5).   
 
1.1.1. Conventional Treatment for Cancer   
 
Today, the mainstays of cancer treatment are surgery, radiotherapy and 
chemotherapy.  Surgery is often done with the aims to cure, relieve symptoms 
and reduce tumor burden. However, surgery is often hindered by tumor 
location, size and ill-defined tumor borders. This is when radiotherapy 
becomes useful to shrink tumor and to cure. In cancer treatment, radiotherapy 
results in deoxyribonucleic acid (DNA) damage in both cancer cells and 
normal cells. For this reason, radiotherapy often causes long-term side effects 
such as fatigue and hair loss.  
 
Although surgery and radiotherapy are potentially curative treatments 
for localized tumor, achieving long term tumor regression with these 
treatments is often limited by the development of tumor relapse. Therefore, 
adjuvant therapies especially chemotherapy are often given. Conventional 
chemotherapy has been dominated by agents with limited selectivity yet high 
toxicities. Considering that cancer is a sophisticated, multi-step disease  
 4 
 
674 10 Leukaemia 
675 9 Bladder 
947 8 Lymphoma 
973 7 Skin  
1198 6 Naropharynx 
1375 5 Stomach 
1700 4 Liver 
2169 3 Prostate 
3828 2 Lung 
3902 1 Colo-rectum 
No.  Ranking Site 
Singapore Man 
645 10 Thyroid 
698 9 Lymphoma 
840 8 Skin 
885 7 Stomach 
1009 6 Cervix Uteri 
1327 5 Ovary 
1332 4 Corpus Uteri 
1868 3 Lung 
3375 2 Colo-rectum 
6798 1 Breast 
No.  Ranking Site 
Singapore Woman 
Table 1.1 Trends in cancer incidence in Singapore 2003-2007. Adapted 
from Reference (5) 
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involving activation and/or abrogation of signal transduction pathways in 
cellular activities (1), cancer cells can continuously evolve and develop 
resistance when only a single chemotherapeutic agent is used. It would be 
ideal if chemotherapy could target various pathways which lead to cancer cell 
death, yet with relatively low toxicity to normal cells. One possible strategy to 
achieve this is by the use of drug combinations as therapeutic regimens. 
 
1.1.2. Rationale for Drug Combinations Approaches in Cancer  
 
The concept of drug combination was founded by Frei and co-workers 
in 1960s where the combination chemotherapy regimens were developed by 
escalating the doses of individual agents to maximum tolerated dose (MTD) 
(6). In this approach, individual agents selected should have different 
mechanism of actions and non-overlapping toxicities (6), with the assumption 
that maximum dose of all drugs would result in maximum therapeutic activity. 
This approach, unfortunately, often results in various toxicity issues as the 
optimization of dose is done based on toxicity rather than efficacy (7-9). In 
addition, the approach of MTD ignores the fact that the degree of synergy 
depends on the concentration and ratio of the combined drugs (9). Therefore, 
better approaches to identify drug combination regimens are necessary.   
 
Ideally, drug combinations used should demonstrate the advantages 
such as broader spectrum of activity, possibility of synergy, less toxicity and 
potentially smaller dose if synergistic. As mentioned, exposure of cancer cells 
to two drugs in combination at a certain concentration ratio can lead to one of 
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the three outcomes: synergistic, additive or antagonistic activity. Synergy is 
defined as the effect of a particular drug combination is greater than that 
achieved with individual agents under similar treatment conditions (10). 
Additivity is defined as the combined effect of two individual agents, while 
antagonistic effect is defined as the production of smaller than expected 
additive effect.  
 
Considering the fact that the ratios of individual agents comprising the 
drug combinations could profoundly influence the therapeutic outcome, 
rationally selecting drug combinations based on their synergistic activity was 
the approach used in the research presented in this thesis. Several 
mathematical models have been developed to test the interaction of drug 
combinations, and the two most commonly used models are the isobolograms 
method (11, 12) and the median-effect principle (10). The isobologram 
method allows the evaluation of a drug combination at a desired effect level, 
but the analysis is only accurate for drugs with similar mechanism of action. In 
addition, a relatively large amount of data is required to have accurate analysis 
of single and drug combination effects. The median-effect principle by Chou 
and Talalay allows the analysis of dose-effect relationships with single and 
multiple drugs, which can then be used to determine the drug interactions (10). 
Compared to the isobologram method, the median-effect principle could also 
be adapted for cell-based screening assays. Therefore, the evaluations of 
selected drug combinations presented in this thesis will be analyzed by the 
median-effect principle.  
 
 7 




 Equation 1 
where Fa = the fraction affected by the dose, Fu= the fraction unaffected 
(where Fu=1-Fa), D= the dose of drug, Dm= the median-effect dose indicating 
potency, m= an exponent representing the shape of the dose-effect curve. The 
median-effect plot determines the median dose, e.g. IC50 from a plot of log 
Fa/Fu versus log D.  
 
To give a quantitative determination of drug interaction, combination 
index (CI) equation was derived from equation 1:  
 
CI = [(D)1 / (Dx)1] + [(D)2 / (Dx)2] +  [(D)1(D)2  / (Dx)1(Dx)2]  Equation 2 
 
where (D)1 and (D)2 are the concentrations of drug 1 and drug 2, respectively, 
that inhibit x% in the actual experiment when they are used in combination.  
(Dx)1 and (Dx)2 are the concentrations of drug 1 and drug 2, respectively, that 
inhibit x% in the actual experiment when they are used as single agents.  Chou 
and Talalay proposed that a CI value of less than 1, equals to 1 or more than 1 
is indicative of a synergistic, additive or antagonistic interaction for a drug 
combination, respectively (10).  
 
Having discussed the approaches which could be used to 
systematically develop anti-cancer drug combinations, the next question to ask 
is how to identify the two (or more) agents for drug combination regimen. The 
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understanding of the molecular effects induced by anti-cancer drugs and the 
processes that contribute to cell death would provide critical information in 
designing effective therapies for cancer treatment. It is therefore instructive to 
review the key pathways involved in cell death mechanisms in the following 
sections.  
 
1.2. The Processes of Cell Death  
 
Under the umbrella of cell death, there are different processes that 
account for the ways in which cells die. Five most widely used classifications 
of cell death have been described based on the differences in the biochemical 
and morphological attributes, which are summarized in Table 1.2. They are 
apoptosis, necrosis, autophagy, senescence and mitotic catastrophe (13). Two 
of these cell death processes, apoptosis and autophagy, are known to be 
“programmed”, which refers to be genetically controlled (14, 15). However, 
there is now growing evidence that necrosis can in certain instances be 
modulated by programmed control mechanisms (14, 16). In the intermediate 
states between life and death exist senescence and mitotic catastrophe, both of 
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Table 1.2 Characteristic of different modes of cell death. Adapted from 




Apoptosis, also known as type I programmed cell death, is derived 
from the Greek terms apó, meaning from and ptosis, meaning fall, and thus 
suggests “falling off”, similar to that of “leaves falling from a tree” (15, 17). 
Apoptosis was first described in 1972 by Kerr et al to differentiate natural cell 
death from necrotic cell death (17). Apoptosis is an important regulatory 
mechanism which is involved in normal cell development and homeostasis. 
During apoptosis, cells first shrink, followed by nuclei condensation. Then, 
cells undergo fragmentation to form “apoptotic bodies” (also known as 
apoptosome), which are phagocytosed by adjacent cells. Therefore, apoptosis 
is considered as an orderly elimination of cells without triggering 
inflammatory response. In general, apoptosis is characterized by several 
distinct morphologic features such as cell membrane blebbing, reduction of 
cellular volume, chromatin condensation and nuclear fragmentation (13-15, 
18).  
 
Apoptosis consists of a complex network of tightly regulated signaling 
pathways. There are two main molecular signaling pathways that lead to 
apoptotic cell death: the intrinsic pathway and the extrinsic pathway (Figure 
1.2). The intrinsic pathway is usually initiated in the presence of intracellular 
stress signals, such as DNA damage, ultraviolet (UV) irradiation, 
chemotherapeutic agents, generation of reactive oxygen species (ROS), viral 
infection and activations of oncogenes (18). On the other hand, 
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Figure 1.2 A schematic illustration of apoptosis pathway highlighting the 
intrinsic and extrinsic pathway. Adapted and modified from Reference (19). 
 
Abbreviations used: DISC, Death-inducing signalling complex; FADD, Fas-
associated death domain; IAP, inhibitors of apoptotic protease; APAF1, 
Apoptotic protease inducing factor 1; SMAC/DIABLO, second mitochondria-
derived activator of caspase/direct IAP binding protein with low pI .  
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 the extrinsic pathway is activated when an extracellular pro-apoptotic ligand 
binds to key pro-apoptotic receptors (also known as death receptor (DR)) on 
plasma membrane. Both intrinsic and extrinsic pathways are mediated by 
caspases. Caspases are intracellular cysteinyl-aspartate-specific proteases 
which exist as pro-enzymes and require proteolytic processing to become 
active (20). There are two groups of caspases. The initiator caspases include 
caspase 8, 9, 10 and the effector caspases include caspase 3, 6, 7. The initiator 
caspases function to cleave and activate effector caspases. Effector caspases in 
turn cleave other protein substrates, including proteins of DNA repair system, 
such as poly-ADP ribose polymerase-1 (PARP-1), to trigger apoptosis.  
 
1.2.1.1. Intrinsic pathway 
 
Apoptosis signaling through the intrinsic pathway is generally 
controlled by the interplay between members of B-cell lymphoma 2 (Bcl-2) 
family (21, 22). The Bcl-2 family proteins are characterized by four highly 
conserved domains called Bcl-2 homology (BH) domains, namely BH1, BH2, 
BH3 and BH4 (23). The number and combination of the BH domains decide if 
the proteins are anti-apoptotic or pro-apoptotic. In brief, anti-apoptotic Bcl-2 
members include Bcl-2, Bcl-xL, Mcl-1, Bcl-w and A1. They have as many as 
four BH domains and are essential for cell survival and normal embryogenesis. 
On the other hand, pro-apoptotic Bcl-2 members lack BH4 domain and can be 
further divided into two groups. The first group has multi-domain, and 
includes Bax, Bak and Bok. The second group has BH3-only domain, and 
includes Bid, Bad, Bim, Puma and Noxa. In response to DNA damage or 
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intracellular stress, the pro-apoptotic Bcl-2 members, most notably Bax and 
Bak, are up-regulated by p53 which is a tumor suppressor gene known as “the 
guardian of genome.” Oligomerization of Bax and Bak causes the formation of 
pores in the inner mitochondrial membrane (IMM) and induces 
permeabilization of the outer mitochondrial membrane (OMM). This leads to 
the release of cytochrome c (Cyt c) from inner mitochondrial membrane space 
into the cytosol. Another pro-apoptotic protein, second mitochondria-derived 
activator of caspase/direct IAP binding protein with low pI (SMAC/DIABLO), 
which interacts with inhibitors of apoptosis proteins (IAP), is also released to 
prevent attenuation of apoptosis. Once in the cytoplasm, Cyt c binds to 
apoptotic protease activating factor-1 (APAF-1) and pro-caspase 9, forming 
apoptosomes. The apoptotic bodies activate pro-caspase 9, which in turn 
activates the effector caspases 3, 6, and 7, hence progressing to apoptosis.  
 
1.2.1.2. Extrinsic pathway  
 
The extrinsic pathway is triggered by the binding of pro-apoptotic 
ligands to death receptors on cell surface (Figure 1.2). The well-established 
pro-apoptotic ligands include tumour necrosis factor (TNF), Fas ligand (Fas-L) 
and apoptosis-inducing ligand 2 or tumor necrosis factor-related apoptosis-
inducing ligand (Apo2-L/TRAIL). TNF binds to TNF receptor (TNF-R), Fas-
L binds to Fas receptor (also known as CD95) and TRAIL binds to TRAIL 
receptor (TRAIL-R). As the Fas-L/Fas receptor is the best characterized 
system, the intracellular cascade of extrinsic pathway will be described using 
Fas-L/Fas receptor as an example.  
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Following Fas-L binding to Fas receptors, a conformational change in 
the intracellular domains of the Fas receptors reveals the presence of a death 
domain (DD). The activation of DDs leads to the recruitment of adaptor 
molecules such as Fas-associated death domain (FADD), which interacts with 
pro-caspase 8 and 10 to form the death-inducing signaling complex (DISC). 
Pro-caspase 8 and 10 are self-cleaved. Activated caspase 8 and 10 in turn 
activate the effector caspases 3, 6, and 7. However, in some cells, such as 
hepatocytes, the extrinsic pathway can intersect the intrinsic pathway where 
caspase 8 induces cleavage of a pro-apoptotic protein Bid. The C-terminal 
truncated form of Bid translocates to mitochondria and activates the intrinsic 
pathway (24).  
 
1.2.2. Necrosis  
 
The term “necrosis” is derived from Greek nekros, which means for 
corpse or deadness (25). Unlike apoptosis, necrosis has been lacking the 
molecular signature, and it is thus referred as an accidental form of cell death. 
This might be true when cells undergo extensive stress or severe physical 
damage. The primary mechanism of necrosis is believed to be the rapid 
depolarization of membranes leading to swelling and rupture of plasma 
membrane (14, 25). Therefore, morphologically, cells undergoing necrosis 
display features such as swelling of organelles which could lead to spillage of 
intracellular contents and rapid mitochondrial dysfunction that leads to 
adenosine triphosphate (ATP) depletion (14).   
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Till date, the causes of necrosis are unclear. Nevertheless, several 
events including ROS generation, overload of calcium ions, activation of 
calpains and cathepsins are reported to be involved in necrotic cell death (14).  
ROS generation can damage DNA, modify proteins and oxidizes 
polyunsaturated fatty acids. DNA damage will lead to activation of a nuclear 
enzyme, PARP-1, which functions to repair DNA damage by poly(ADP-
ribosyl)ation (26, 27). Poly(ADP-ribosyl)ation is a process where ADP-ribose 
units are added to DNA-binding proteins. The substrate for poly(ADP-
ribosyl)ation is nicotinamide adenine dinucleotide (NAD
+
), which in addition 
to its function as a co-factor in redox reactions to accept electrons, is 
catabolized to release nicotinamide and ADP-ribose. PARP-1 catalyzes the 
binding of the first ADP-ribose onto DNA-binding proteins and subsequent 
elongation with additional ADP-ribose units. While cells attempt to restore 
NAD
+ 
by recycling nicotinamide with two ATP molecules, excessive 
activation of PARP-1 depletes NAD
+ 
pool and ATP. Therefore, in the event of 
extensive DNA damage, massive synthesis of poly(ADP-ribose) drives the cell 
to death by necrosis. On the other hand, when DNA damage is mild, PARP-1 
undergoes rapid cleavage and inactivation, and hence, cells die by apoptosis 
and intracellular ATP remains preserved (27). The role of ROS in mediating 
cell death is further described in Section 1.3.  
 
Overload of intracellular calcium, which is caused by an influx of 
calcium ions or release of calcium ions from endoplasmic reticulum (ER) into 
cytosol, leads to the opening of mitochondria permeability transition pores 
(MPTP) (28). This will depolarize inner mitochondrial membrane, uncouple 
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oxidative phosphorylation and cause the swelling of mitochondrial matrix. 
Eventually, mitochondrial outer membrane ruptures, and cells die by necrosis. 
Furthermore, overload of intracellular calcium activates calcium-dependent, 
ATP-independent proteases calpains, which functions to cleave the plasma 
membrane sodium/calcium exchanger (29). As a result, sustained increase in 
intracellular calcium ions occurs. In the event when lysosomal plasma 
membrane is cleaved by calpains, cathepsins will be released to induce 
proteolysis, followed by necrotic cell death (14).  
 
For a long time, necrosis has been considered as an “uncontrolled” 
form of cell death. More recently, accumulating evidence has emerged to 
convey a distinct view of necrosis, describing that necrosis can be tightly 
regulated (14, 16). Terms such as “programmed necrosis” and “necroptosis” 
have recently been introduced to describe this type of cell death, which 
preferentially depends on the activation of a  serine/threonine kinase known as 
receptor-interacting protein 1 (RIP1) (14, 30). Programmed necrosis is 
reported to be activated by various ligand-receptor interactions, including DR 
(31), toll-like receptor (TLR) (32) and PARP-1 (33, 34). In particular, the 
signaling pathway involving TNF-α has gained much attention. Vercammen et 
al reported that in mouse fibrosarcoma L929 cells, caspase inhibition by a pan-
caspase inhibitor, z-VAD-fmk did not prevent TNF-α induced cell death (31). 
Rather, caspase inhibition directed cells to programmed necrosis. Likewise, 
TNF-α or Fas-L triggered necrosis in RIP1
-/-
 Jurkat cells or in the presence of 
z-VAD-fmk (35, 36). Besides DR-induced necrosis, activation of TLR by 
lipopolysaccharide (LPS) induced a RIP1-dependent necrosis in macrophages 
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when caspase 8 was inhibited (32). In addition, activation of PARP-1 by a 
DNA alkylating agent, N-methyl-N-nitro-N-nitrosoguanidine (MNNG), has 




mouse embryonic fibroblast (MEF) 
cells (34). With the present knowledge of programmed necrosis, it appears that 
the understanding of mediators and how the cellular processes interplay in 




Autophagy is derived from the Greek words phagy which means “to 
eat” and auto which means “oneself” (37). Autophagy denotes the process by 
which cells degrade intracellular constituents through a regulated lysosomal 
pathway. It is thought to be a process which occurs at low basal level in all 
cells for turnover of cellular components and homeostasis (37, 38). However, 
when cells are subjected to sublethal stress such as nutrient deprivation, 
autophagy is up-regulated to recycle their own damaged organelles, redundant 
or non-essential components for the conservation of nutrient and energy (15).  
 
Three types of autophagy have been defined in mammalian cells based 
on how lysosomes receive the contents for degradation (39). The type with the 
most extensive description is macroautophagy which is mediated by the 
sequestration of cytosolic portions through the formation of double membrane 
vesicles referred as autophagosomes. These autophagsomes then fuse with 
lysosomes to form autolysosomes, where the contents are degraded by 
hydrolases in lysosomes. An overview of macroautophagy process is shown in 
 18 
Figure 1.3. The second type is microautophagy, where a small portion of 
cytoplasm is directly invaginated by lysosome membrane itself. This is also a 
degradation mechanism for organelles and long-lived proteins, but, unlike 
macroautophagy, it is not responsible for the adaptation of nutrient deprivation. 
The third type is called chaperone-mediated autophagy (CMA), which 
degrades selectively cytosolic proteins containing KFERQ-like motifs. 
KFERQ is a specific pentapeptide with lysosome-targeting motif that is 
present in about 30% of cytosolic proteins, including ribonuclease A (RNase 
A) that cleaves single-stranded RNA and the amyloid precursor protein (APP) 
which is found in synapses of neurons. This motif is recognized by the 
cytosolic chaperone, heat shock 73-kDa protein (Hsp73), which delivers the 
proteins into lysosome when Hsp73 binds to lysosome-associated membrane 
protein 2a (LAMP 2a). However, it remains unclear how these KFERQ-like 
motifs are recognized by chaperone.  
 
Macroautophagy (hereafter autophagy) has been suggested as a way to 
conserve energy during metabolic stress such as nutrient starvation. The core 
pathway involved in autophagy is the mammalian target of rapamycin (mTOR) 
pathway. mTOR, which functions as a nutrient sensor, is also a negative 
regulator of autophagy. During nutrient deprivation, mTOR repression shifts 
the cellular process from protein synthesis toward autophagy to recycle 
cytosolic constituents (38, 39). Downstream of mTOR, there are genes which 
are termed autophagy-related genes (Atg) that are essential for encoding the 
proteins needed for the induction of autophagy and related pathways (41). 



















































Figure 1.3  An overview of macroautophagy process. Adapted from Reference 
(40). During starvation, inhibition of mTOR triggers autophagy which is 
initiated by ULK1 complex. Autophagy begins with the isolation of membrane 
(phagophore). Atg 7 activates Atg 12 and Atg 12 is transferred to Atg 10 
before conjugates with Atg 5.  Then, Atg 16 conjugates to Atg12-Atg5 and 
attaches Atg12-Atg5-Atg16 complex to phagophore. The membrane elongates 
and beclin-1 is activated. Autophagosome, a double membrane structure which 
could engulf intracellular organelles such as mitochondria and Golgi apparatus 
is formed. LC3 is cleaved by Atg 4 to form LC3-I, which is then modified with 
a lipid attachment to form LC3-II. LC3-II is translocated to the autophagosome 
membrane. When the autophagosome fuses with lysosome, autolysosome is 
formed where hydrolase enzyme in lysosome degrades the sequestered content. 
3-MA inhibits LC3-II during autophagosome formation while BA1 inhibits the 
fusion between autophagosome and lysosome.  
 
Abbreviations used: AMPK, AMP-activated protein kinase; mTOR, 
mammalian target of rapamycin; ULK1, Unc-51-like kinase 1; Atg, autophagy-






 kinase activity of Unc-51-like kinase 1 (ULK1), the mammalian ortholog of 
the yeast Atg 1 (41, 43). During starvation, inhibition of mTOR triggers 
autophagy which is initiated by ULK1 complex consisting of ULK 1, Atg 13 
and focal adhesion kinase family protein of 200 kDa (FIP200), the mammalian 
homolog of the yeast Atg 17. This is followed by the expansion of the 
autophagosomes membrane (also known as phagophore) that is dependent on 
Atg 12. At first, ULK1 complex activates Atg 7 which in turn activates Atg 12. 
Then, Atg 12 is transferred to Atg 10 and finally conjugated to Atg 5 (39, 42). 
Once formed, Atg12-Atg5 conjugate interacts with Atg 16, which attaches the 
Atg12-Atg5-Atg16 complex to autophagosomes membrane (43). Two other 
molecules essential for regulating autophagosomes formation are light chain 3 
(LC3) (44) and beclin-1 (45). LC3 is cleaved by Atg 4 into the cytosolic form, 
LC3-I. Similar to Atg12-Atg5 conjugate, Atg 7 activates LC3-I and transfers it 
to Atg 3. LC3-I is then modified with a lipid attachment to form membrane-
bound LC3-II, facilitated by the Atg12-Atg5 conjugate (44, 46). LC3-II is not 
only an essential step during autophagosome membrane formation, but it also 
serves as a hallmark for detecting autophagy (37, 39). Beclin-1 is a component 
of class III phosphatidylinositol-3 kinase (PI3K) that regulates the formation 
of autophagosomes (45). Interestingly, beclin-1 is found to interact with 
members of Bcl-2 family proteins such as Bcl-2 and Bcl-xL through a BH3-






1.2.3.1. Autophagy and cell survival  
 
The role of autophagy in cancer has been described as a double-edged 
sword due to its controversial involvement in both cell survival and cell death 
(38, 39, 49). As mentioned above, autophagy serves as a process to recycle 
nutrients, maintain cellular energy and sequestrate damaged organelles, 
especially under stress conditions, thus representing a protective strategy for 
cells to avoid damage (39, 41, 50). The observation that premalignant rat 
pancreatic cancer cells show increased levels of autophagy further supported 
the potential of autophagy as a survival advantage in cancer cells (51). 
Additional evidence for the pro-survival activity of autophagy comes from 
studies in which Atg genes were knocked down and increased in cell death 
was observed. For example, the silencing of beclin-1 or Atg 5 was reported to 
enhance starvation-induced or stress-induced cell death in Hela cells (52).  
 
1.2.3.2. Autophagy and cell death  
 
Although known as Type II programmed cell death, the precise role of 
autophagy in executing cancer cell death is debatable. The concept of 
“autophagic cell death” is mainly based on the observation that the dying cells 
possess autophagic features and inhibition of autophagy could decrease cell 
death (40). Shimizu et al reported that when caspase inhibitor z-VAD-fmk was 
added to mouse fibroblasts L929, knockdown of Atg 7 or beclin-1 suppressed 
cell death (53). Furthermore, when breast cancer cells MCF-7 were treated 
with tamoxifen, cell death with autophagic features was observed (54), as do 
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glioma cells when treated with arsenic trioxide (55). It is worth noting that 
autophagy probably functions initially as a protective mechanism in most of 
the situations. However, if cellular damage is too extensive, excessive 
autophagy induction might lead to cell death. More appropriately, cell death 
associated with autophagic features has been described as the outcome of 
failed adaptation where progression of the autophagy process passes the point 




The term senescence is derived from the Latin word “senex”, which 
means old age (56). As mentioned previously, senescence is not a form of cell 
death but rather an irreversible growth arrest of cells in the G1 cell cycle phase 
(57). Senescence is known as an essential process of aging due to shortening 
of telomeres (13, 56, 57). Telomeres are repetitive DNA sequences that protect 
the ends of chromosomes from instability and activation of DNA damage in 
cells. After each cell division, telomeres in human cells progressively shorten 
due to the erosion of the telomeric repeats. Most adult cells lack enough 
telomerase to add telomeres repeats to chromosome end. After telomeres 
shorten beyond a limit, they are recognized as DNA breaks, and subsequently 
activate DNA damage response and cell cycle arrest. Besides aging, other 
common causes for senescence include oxidative stress, activated oncogenes, 
cytotoxic drugs and irradiation (57). Senescent cells are identified by 
distinctive morphological changes as increase in cell size, cell flattening, 
formation of vacuoles, and accumulation of senescence-associated 
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heterochromatin foci (SAHF) and senescence-associated β-galactosidase (13, 
57).  
 
Senescence is controlled by tumor suppressor genes, in particular the 
p53 and retinoblastoma (Rb) pathway (58). During DNA damage, p53 is 
activated to induce apoptosis or senescence, and the choice is proposed to be 
decided by the activation of the downstream target genes. In apoptosis, p53 
leads to PUMA and NOXA activation while in senescence, the activation of a 
cyclin-dependent kinase (Cdk) inhibitor, p21 is favoured (57). As the 
progression through cell cycle is mainly controlled by the activity of Cdk, the 
activation of p21 produces the initial cell cycle arrest. Another Cdk inhibitor 
which is up-regulated during senescence is p16. p16 can activate Rb protein, 
which binds to Cdk4 and Cdk6 to repress their roles in cell cycle progression.   
 
1.2.5. Mitotic catastrophe 
 
Similar to senescence, mitotic catastrophe is considered as an 
irreversible trigger which leads to death. Mitotic catastrophe results from 
improper segregation of chromosomes during mitosis (59, 60). As a result, 
giant cells with either micronuclei or two nuclei are formed by fusion of 
daughter cells, abnormal cell division or the combination of the two. Although 
apoptotic cells may also have fragmented nuclei, apoptotic cells can be 
differentiated by their shrunken cytoplasm and condensed chromatin (61). 
Mitotic catastrophe could proceed through several mechanisms such as cell 
cycle checkpoint deficiencies and interference with microtubule assembly, but 
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the final step is always the formation of nuclear envelopes around individual 
clusters of missegragated chromosomes. There are a number of causes for 
mitotic catastrophe, including ionizing radiation, mitotic failure due to cell 
cycle checkpoints defection and chemotherapies that affect the stability of 
microtubules (60). Mitotic catastrophe is regulated by various proteins, 
especially the Cdk, checkpoint kinases (Chk), aurora kinases and polo-like 
kinases. While apoptosis and senescence are regulated mainly by p53, mitotic 
catastrophe is not (62).   
 
1.3. Reactive Oxygen Species (ROS)  
 
Having discussed the processes of cell death, the following sections 
focus on ROS, which are widely recognized as the central signaling molecules 
regulating not only cell survival, but also different modes of cell death (63, 64). 
Further understanding of such an important mediator in cell death mechanisms 
may reveal potential targets for therapeutic intervention. ROS is a collective 
term to describe oxygen-derived species, including not only the free radicals 
which contain an unpaired electron such as superoxide (O2
·-
) and hydroxyl 
radical (OH·), but also non-radical derivatives of oxygen such as hydrogen 
peroxide (H2O2). ROS are generally small, short-lived and highly reactive 
molecules. Specifically, O2
·- 
and OH· are extremely unstable whereas H2O2 are 




1.3.1. Biological sources and anti-oxidant defense mechanism of ROS  
 
There are numerous sources of ROS including ionizing radiation on 
biological molecules, synthesis by enzymes such as nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase from phagocytic cells as well as the 
by-product of respiration in mitochondria electron transport chain. During 
respiration, about 1-2% of oxygen consumed is not completely reduced to 
water (H2O), but is instead partially reduced to O2
·-
 along the respiratory 
electron transport chain, and subsequently converted to H2O2 (66, 67). Because 
O2
·- 
is constantly generated during respiration, mitochondria are considered the 
major site of endogenous ROS production (68). Mitochondria have outer and 
inner membranes which are separated by an intermembrane space (Figure 1.4). 
The presence of pore protein such as porin or voltage-dependent anion channel 
(VDAC) renders the mitochondrial outer membrane permeable to small 
molecules and ions (70). Conversely, the inner membrane is impermeable to 
majority of small molecules except water, oxygen, carbon dioxide and 
ammonia (71). The respiratory electron transport chain is located in the inner 
mitochondria membrane and is composed of four integral membrane protein 
complexes (complex I, II, III, IV), ADP-ATP translocases and ATP synthase 
(69). Complexe I, also known as NADH-dehydrogenase, accepts electrons 
from NADH. Complex II, succinate dehydrogenase, receives electron from 
succinate. Both complexes then transfer the electrons to ubiquinone 
(coenzyme Q) which passes the electrons to Complex III (ubiquinol-
cytochrome c oxidoreductase). Electrons are transferred to Cyt c, and lastly to 







































































Figure 1.4 Generation of ROS and anti-oxidant defense system in 
mitochondria. Adapted from Reference (69). (i) Complex I and Complex II 
receive electrons from NADH and succinate, respectively. Electrons are passed 
to Coenzyme Q to Complex III, to Cyt c and finally to Complex IV. At 





 generated at Complex I is only released into the 
mitochondria matrix, whereas the O2
·-
 generated at Complex III can either be 
transferred to the mitochondria matrix or intermembrane space. (iii) At 
mitochondria matrix, O2
·-
 can be converted to H2O2 by MnSOD, and H2O2 can 
be scavenged by GPx to form H2O. Alternatively, O2
·-
 gains access to cytosol 
through VDAC or MPTP. At cytosol, O2
·-
 is converted to H2O2 by Cu/ZnSOD. 
H2O2 in cytosol is converted to H2O by catalase. (iv) O2
·-
 at the intermembrane 
space are dismuted to H2O2 by Cu/ZnSOD. (v) Uncharged H2O2 passes to 
cytosol and converted to H2O by catalase.  
 
Abbreviations used: CoQ, coenzyme Q; Cyt c, cytochrome c; O2
·- 
, superoxide; 
H2O2, hydrogen peroxide;  MnSOD, manganese superoxide dismutase; GPx, 
gluthathione peroxidase; H2O, water; VDAC, voltage-dependent anion 
channel; Cu/ZnSOD, copper and zinc SOD; CypD, cyclophilin D; ANT, 
adenine nucleotide translocator; MPTP, mitochondria permeability transition 
pore; IMM, inner mitochondrial membrane; OMM, outer mitochondrial 
membrane.  
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 The generation of O2
·-
 mainly takes place at complex I and III. At complex III, 
the O2
·-
 generated can either be transferred to the mitochondria matrix or 
intermembrane space whereas the O2
·-
   generated at complex I is only released 
into the mitochondria matrix. The burden of ROS production is largely 
counteracted by an anti-oxidant defense system that includes the enzymatic 
scavengers superoxide dismutase (SOD), catalase and glutathione peroxidase 
(GPx). At mitochondria matrix, O2
·-
 can be converted to H2O2 by manganese 
superoxide dismutase (MnSOD), and H2O2 can be scavenged by GPx to form 
H2O. Alternatively, the ROS at matrix can also pass through MPTP, which is 
formed by VDAC, cyclophilin D (Cyp D) and the adenine nucleotide 
translocator (ANT), to enter into cytosol and induce cell death.  For O2
·-
 which 
is released into the intermembrane space, they are dismuted to H2O2 by copper 
and zinc SOD (Cu/ZnSOD). Uncharged H2O2 can pass through the 
mitochondria membrane to cytosol, where it will be converted to H2O by 
catalase.  
 
1.3.2. ROS and cancer 
 
Increased generation of ROS has long been observed in cancer cells, 
compared to their normal counterparts (72, 73). For example, increased ROS 
levels were shown in leukemia cells (74), and oxidized DNA was found in 
clinical solid tumor specimens (75, 76). In addition, anti-oxidant enzymes are 
over-expressed in cancer cells, implying their higher intrinsic oxidative stress 
(77, 78). Despite the prevalent ROS is observed in a variety of tumor cells, the 
precise mechanisms responsible for such oxidative stress remain to be defined. 
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The degree of oxidative stress is known to be dependent on the balance 
between ROS production and its elimination (65). It is interesting to note that 
an increase in ROS can induce various biological responses, ranging from 
increase cell proliferation and differentiation to oxidative damage which leads 
to cell death. 
 
1.3.2.1. ROS and cell survival  
 
Although traditionally, ROS are considered as toxic by-products, their 
role as intracellular signaling molecules in deciding the fate of cells have also 
been documented. Under physiological conditions, low levels of ROS are 
important in maintaining cellular redox balance and in signaling cellular 
proliferation (79, 80). ROS are shown to activate signaling molecules such as 
protein kinases and transcription factors, including nuclear factor kappa B 
(NF-κB) (81), hypoxia-inducible factor-1 α (HIF-1α) (82), and stress-activated 
protein kinase (SAPK, also known as JNK) (65, 83). As a result, anti-apoptotic 
proteins and gene expression that facilitate adaptation were increased (63). 
Recently, increasing evidence suggests a link between ROS and autophagy, 
indicating that ROS are important regulators of autophagy. ROS were shown 
to oxidize Atg 4 (84) and activate beclin-1 (85), leading to autophagy 
induction. In another study, Huang et al showed that H2O2 induced autophagy 




 MEFs, as suppression of 
autophagy by knockdown of Atg 5 or Atg 7 increased cell death under 
oxidative stress (86). In addition, Kim et al reported that selenite induced O2
·-
 
generation and subsequently triggered cell death with autophagic features in 
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glioma cells T98G (87, 88). The mechanism for ROS regulation of autophagy 
seems to depend on cellular context and autophagic stimulus because two 
distinct responses have been reported. One key role of these autophagy 
processes was to counteract the damaging effect of ROS. However, when the 
damaging effect was beyond the autophagic capacity, cell death was observed.  
 
1.3.2.2. ROS and cell death  
 
On the other hand, excessive production of ROS may inflict 
irreversible damages to cellular components including lipids, DNA and 
proteins, thus provoking cell death (63, 89). As ROS are highly reactive in 
nature, they could attack various components of DNA such as DNA bases and 
deoxyribose sugar, and cause DNA with cross-linking of protein. ROS could 
mediate protein damage by inducing peptide cleavage and direct oxidative 
modifications to amino acid side chains (90). In addition, lipid membranes are 
also vulnerable to ROS attack. When lipids are oxidized, more radicals are 
produced, which in turn, lead to a vicious cycle and substantial cellular 
damage. When membrane permeability increases, especially at the 
mitochondria where majority of the ROS are generated, MPTP is triggered to 
open and Cyt c is released (91). This process activates the apoptotic cascade. 
However, a burst in intracellular ROS level imparts massive oxidative damage 
and leads to necrotic cell death (63, 92, 93). Due to the reactive chemical 
nature of ROS, DNA lesion caused by ROS is considered the most common 
type of damage (93). Hence, it is not surprising that ROS are also involved in 
cellular senescence and mitotic catastrophe (94).  
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1.4. Overview of sphingolipids   
 
Current knowledge on cancer cell death and signaling has helped in the 
discovery of new and effective therapeutic strategies. In search of novel anti-
cancer treatments, the sphingolipid pathway is receiving significant attention 
over the last decade. Sphingolipids are amphipathic molecules that have both 
hydrophobic and hydrophilic properties. Compared to phospholipids which are 
the fundamental building blocks of cellular membrane that consist of a polar 
phosphate head group and a pair of non-polar acyl chains connected by ester 
bonds to a glycerol backbone, sphingolipids are consisted of a polar amino 
group and a single non-polar fatty acid tail (Figure 1.5). Additionally, the 
backbone of sphingolipid is a sphingoid base (a 2-aminoalk [ane or ene]1,3-
diol) or generally referred to as sphingosine, an amino alcohol, as opposed to 
the glycerol backbone of phospholipids (Figure 1.5). The amino group of 
sphingosine can form an amide linkage with a fatty acid carboxyl and form 
ceramide (Figure 1.5). In more complex sphingolipids, additional polar group 
is esterified to the terminal hydroxyl of the sphingosine moiety of ceramide.  
 
Although sphingolipids were once believed to play a primarily 
structural role in regulating the fluidity of cell membrane (95), it has become 
evident that they also have important roles in intracellular signaling. The 
discovery of their involvement in pathogenesis of human disorders, such as 
cancer, inflammation, neurological, immune and metabolic disorder (95, 96), 
has made them known as bioactive lipids. Bioactive lipids are defined as lipids 
derived from components of the cellular membrane that mediate cellular 
function (97). Among these bioactive lipids, much emphasis has been placed 
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Figure 1.5 Structures of phospholipid and sphingolipid. Phospholipid 
has a glycerol backbone, two acyl chains and a phosphate group 
which allows the attachment of different head groups. Sphingolipid 
has a sphingosine backbone which is consisted of an amino group and 
a fatty acid chain. Different attachments of functional groups at R and 
R’ give rise to different types of sphingolipids.  
General structure of phospholipid 








Sphingosine backbone    
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on ceramide and sphingosine-1-phosphate (S1P). Ceramide and S1P exert 
opposite effects in cells, with ceramide usually promoting apoptosis (98) while 
S1P inducing cell proliferation (99). The balance between ceramide and S1P is 
described as the sphingolipid rheostat (Figure 1.6) (100). As ceramide and 
S1P are the best-studied bioactive lipids, the role of sphingolipids in cell 
survival and cell death will be illustrated using S1P and ceramide as the 
examples, respectively. 
 
1.4.1. Sphingolipids and cell survival  
 
Upon the addition of a phosphate group to sphingosine by sphingosine 
kinase (SK), S1P is formed (Figure 1.6). The observations that S1P regulates 
cell growth (99, 100) and suppresses apoptosis (101) attracted many 
researchers to investigate S1P as a bioactive lipid mediator. This interest has 
led to the discovery of a myriad of essential cellular processes caused by S1P 
in addition to the aforementioned effects on cell growth and survival, 
including to name just a few, cell invasion, angiogenesis, and vascular 
maturation (100, 102). Compelling evidence also supported the role of S1P in 
facilitating cancer cell proliferation. For example, increased S1P levels were 
shown to promote proliferation and survival in many cancers, including 
human glioma, colon and breast cancer cells (103-105). Currently, numerous 
studies are underway to investigate the potential of new therapies targeting 





Figure 1.6 Sphingolipid rheostat. The decision of cell death and survival 
can be affected by the balance between ceramide and S1P. 
 
Abbreviation used: S1P, sphingosine-1-phosphate. 
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1.4.2. Sphingolipids and cell death 
 
As opposed to S1P, ceramide exerts effects on various biological 
functions such as apoptosis, growth arrest and senescence. Thus, ceramide is 
also gaining recognition as a tumor suppressor lipid (96, 97). The production 
of ceramide is associated with numerous stress stimuli. It is therefore not 
surprising that many cytokines, environmental stresses, ionizing radiation and 
chemotherapeutic agents, including exogenous cell-permeable ceramides, 
could induce rapid endogenous ceramide generation to initiate apoptosis. 
Ceramide mediates its anti-proliferative activity by regulating its downstream 
targets, including protein kinase C (PKC), mitogen-activated protein kinase-
extracellular signal-regulated kinase (MAPK-ERK), PI3K-Akt signaling 
cascades. In addition, ceramide induces senescence by the activation of Rb, 
activation of p21 and inhibition of Cdk (107).  
 
1.4.3. Safingol  
 
In light of the role of sphingolipids have in cancer, the research 
presented in this thesis has focused on the study of a saturated analog of 
sphingosine, safingol, or (2S, 3S)-2-amino-1,3-octadecanediol. It is a synthetic 
L-threo isomer of dihydrosphingosine (108, 109). Safingol has a long 
sphingoid base with 18 carbons and a polar end consisted of hydroxyl and a 
weakly basic primary amino group. Safingol has two asymmetric chiral 
carbons, and therefore, may exist as four stereoisomers. The natural sphingoid 
base which exists in D-erythro (2S, 3R) configuration and the two other 
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stereoisomers [(2R, 3R) and (2R, 3S)] were reported to display biological 
activity such as binding to SK (110, 111). However, safingol, the L-threo 
isomer, (2S, 3S) is of particular interest due to its anti-cancer activities. 
Furthermore, Buehrer and Bell showed that compared to the erythro isomer, 
the L-threo isomer of sphingosine demonstrated strong inhibition of SK from 
rat brain and human platelets (112). The chemical structures of safingol and its 
isomers are shown in Figure 1.7. Due to the presence of a hydrophobic chain 
and a polar head group, safingol forms micelles in water (113). Physically, 
safingol appears as a white to off-white crystalline solid with a molecular 
weight of 301.51. Safingol has limited aqueous solubility but is known to be 
soluble in ethanol between 7.5-8.2 mg/mL. Previously, safingol was 
administered in an emulsion in a pilot study (114). 
 
Currently, safingol in combination with cisplatin is under phase I 
clinical studies for patients with advanced solid tumors, in which preliminary 
data showed promising activity in refractory adrenocortical cancer (115). In 
addition, several in vitro and in vivo studies demonstrated that safingol 
augmented the efficacy of other chemotherapeutic agents, including N-(4-
hydroxy-phenyl)retinamide (fenretinide), mitomycin-C, cisplatin, 1-beta-D-
arabinofuranosylcytosine (ara-C) and vinblastine in a variety of tumor cell 
lines (109, 114, 116-120). More importantly, safingol has been demonstrated 
to reverse the multidrug resistance of a doxorubicin-resistant breast cancer cell 
line, MCF-7 DOX
R
, by increasing the accumulation of vinblastine (120). 
Several mechanisms on how safingol enhances the cytotoxicity of 
chemotherapeutic agents have been proposed. Schwartz et al reported that 
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Figure 1.7 Chemical structures of safingol and its isomers. Adapted 
from Reference (108). 
R = C15H31- 











 safingol potentiated mitomycin-induced apoptosis in gastric cancer cells, 
presumably via the inhibition of PKC. In parallel, safingol has been shown to 
potentiate ara-C-induced apoptosis in leukemia HL-60 cells, possibly by 
inhibition of atypical PKC ζ and MAPK ((118). In another study by Maurer et 
al, safingol demonstrated synergistic effect with fenretinide in neuroblastoma, 
lung, melanoma, prostate, breast, pancreas and colon cancer cells, however, 
the exact mechanisms of how safingol synergized with fenretinide was unclear 
(119). In this regard, Maurer et al proposed that safingol activated the pro-
death associated JNK/SAPK while fenretinide induced ceramide production 
(119). Despite of the accumulating evidence suggesting the therapeutic 
potential of safingol, the underlying mechanism of safingol remains largely 
unknown. These observations have prompted the work conducted in this thesis, 
in which the mechanisms of safingol were investigated. Before describing this 
work, it will be instructive to review the molecular effects of safingol reported 
to date.   
 
1.4.3.1. Molecular effects induced by safingol treatment 
 
Safingol was previously shown to act as a competitive inhibitor of SK 
(112) and PKC (120-122). A brief description on PKC and SK inhibition by 
safingol as well as recent findings on the molecular effects induced by safingol 





1.4.3.1.1. Protein kinase C (PKC) inhibition 
 
Activation of PKC can lead to a variety of cellular signaling pathways, 
including cell growth, cell cycle progression, drugs efflux and cancer cell 
angiogenesis. The main pathway which is activated by PKC is the MAPK-
ERK pathway (Figure 1.8). Studies have shown that PKC activates Raf1, 
which in turn phosphorylates MEK1 and MEK2 and activates the MAPK 
cascade resulting in gene transcription and cell proliferation. In addition, PKC 
can also activate transcriptional factors NF-κB (123). NF-κB controls the 
expression of urokinase-type plasminogen activator (uPA) and its receptor, 
thus playing a role in cancer cell invasiveness. PKC also induces the secretion 
of matrix metalloprotinases, in particular matrix metalloprotinases-9 and -2, 
which are involved in cancer cell invasion.  
 
PKC belongs to a serine/threonine kinase family which consists of at 
least 10 distinct isoforms (124, 125). Depending on their activation 
requirement, PKC isoforms have been grouped into three classes. The 
conventional (also known as classical) class of PKC includes PKC α, βI, βII 
and γ. They are activated in the presence of calcium or a lipid messenger 
diacylglycerol (DAG). The novel PKC isoforms include PKC δ, ε, η and θ, 
and they are activated by DAG but not calcium. The atypical PKC isoforms 
are PKC ζ and ι where their activations are independent of both calcium and 
DAG. Each PKC has an amino regulatory domain and a carboxyl catalytic 
domain. The structures of the three classes of PKC are shown in Figure 1.9. 
PKC posseses regions that are highly conserved in all isoforms, called C1-C4 
regions. At the catalytic domain, C3 and C4 region represents the binding site 
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Figure 1.8 PKC signaling pathway. Adapted from Reference (125). Activation 
of PKC leads to Ras-Raf1-MEK-ERK pathway. In addition, PKC activates 
NF-κB. A variety of signaling pathways lead to cell growth, cell cycle 
progression, migration and drug efflux.  
 
Abbreviations used: PLC, phospholipase C; DAG, diacylglycerol; PKC, 
protein kinase C; ERK, extracellular signal-regulated kinase; NF-κB, nuclear 
factor kappa B.  
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Figure 1.9 Structure of a PKC. Adapted from Reference (125). PKC has a 
regulatory and catalytic domain. PKC posseses regions that are highly 
conserved in all PKC isoforms, called C1-C4 regions In the conventional 
PKC, the regulatory domain consists of a PS, CR and C2 region. The PS in 
the regulatory domain causes auto-inhibition by binding to substrate-binding 
site (C4) in the catalytic domain.  DAG binds to the CR regions at the 
regulatory domain while calcium binds to the C2 regions. At the catalytic 
domain, C3 region represent the binding site for ATP. Novel PKC have a 
C2-like region, but it is unable to bind to calcium. Atypical PKC lack a CR 
and C2 region. 
 
Abbreviations used: PKC, protein kinase C; PS, pseudosubstrate; CR, 
cysteine-rich; DAG, diacylglycerol; ATP, adenosine triphosphate; Ca
2+
, 
calcium ion.  
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for ATP and substrate, respectively. The regulatory domain is consisted of a 
C1 and C2 region, and C1 region is comprised of a pseudosubstrate (PS) and 
cysteine-rich (CR) regions. When PKC assume an inactive conformation, the 
PS in the regulatory domain binds to the substrate-binding site, C4 region, in 
the catalytic domain (Figure 1.9).  The CR regions are the binding sites for 
DAG while the C2 region is the binding site for calcium.  
 
Safingol has been reported to be an inhibitor of various PKC isoforms, 
including PKC α (120, 126), ζ (118), β, δ and ε (127). Previous studies 
suggested that safingol bind to the regulatory domain in PKC by displacing 
DAG from its binding site (122, 128). Specifically, safingol inhibited purified 
rat brain PKC enzyme activity and PKC α in MCF-7 DOX
R
 with an IC50 value 
of 37.5 and 40 ± 8 µM, respectively (120).   
 
1.4.3.1.2. Sphingosine kinase (SK) inhibition 
 
In addition to PKC inhibition, safingol is also known to inhibit SK 
(112). SK is predominantly a cytosolic enzyme and critical regulator of the 
sphingolipid rheostat where it converts sphingosine to S1P. The signaling 
pathways of SK-S1P are shown in Figure 1.10. Multiple growth factors and 
cytokines activate SK in a PKC- and ERK-dependent manner, which 
subsequently induce the translocation of SK to the plasma membrane. SK 
phosphorylates sphingosine to form S1P, and S1P binds to S1P receptor at the 
plasma membrane. Primarily, S1P activates Rac, Ras-ERK, PI3K-Akt-Rac 
pathways (97, 129). As a result, SK, through the formation of S1P, has been  
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Figure 1.10 SK-S1P signaling pathway. Adapted from Reference (97, 129). 
Upon phosphorylation by growth factor and cytokine, SK converts sphingosine 
to S1P. When S1P binds to S1P receptor, downstream pathways including Rac, 
Rac-ERK, P13K-AKT-Rac and PLC are activated. As a result, cellular 
motility, proliferation, migration and survival are induced.   
 
Abbreviations used: PKC, protein kinas C; ERK, extracellular signal-regulated 
kinase; SK, sphingosine kinase; S1P, sphingosine-1-phosphate; PI3K, 
phosphatidylinositol-3 kinase; PLC, phospholipase C.  
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implicated in various cellular processes such as cell proliferation, migration, 
invasion and angiogenesis (129-131). Over-expression of SK could result in 
cellular transformation and tumor progression in 3T3 cells (132). Messenger 
ribonucleic acid (mRNA) levels of SK are significantly increased in various 
cancers such as breast, colorectal, stomach, lung, ovary, and kidney (133), and 
may lead to decreased apoptosis and increased cell proliferation (134, 135). 
 
Looking at the structure of SK, two human SK isoforms have been 
identified (136). They are SK1 and SK2. SK1 is mostly expressed in the brain, 
heart, thymus, spleen, kidney and lung (137) while SK2 is found 
predominantly in kidney and liver (138). SK has five conserved regions, C1-
C5 (129, 136) (Figure 1.11). C1-C3 regions are the catalytic domain of the 
enzymes and they share homology with other lipid kinase such as DAG kinase. 
The C4 domain is specific to SK while the C5 domain is conserved in DAG 
kinase. Recently, ATP has been reported to bind to the C2 domain of SK (135) 
while sphingosine was suggested to bind to the C4 domain (139). 
 
Previously, Stoffel et al reported that the Km of safingol to platelet-
derived SK was 10
-3
 M (110). Apart from this finding, Stoffel et al also 
demonstrated that dihydrosphingosines inhibited 50% of SK reaction between 
0.35 and 3.6 Χ 10
-4
 M (110). This study was supported by the subsequent 
findings that the threo-isomers of dihydrosphingosine inhibited purified SK 
enzyme from rat brain and human platelets with a dissociation constant for 
inhibitor (Ki) of 0.21 and 0.10, respectively (112). However, the exact nature 
of how safingol interacts with SK is not fully understood till date. 
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catalytic domain  




Figure 1.11 Structure of SK. Adapted from Reference (136). SK has five 
conserved regions (C1-C5). C1-C3 regions are the catalytic domain where 
ATP binds. C4 region is specific to SK and suggested as the binding site for 
sphingosine. C5 is the binding site for calcium.  
 
Abbreviations used: SK, sphingosine kinase; ATP, adenosine triphosphate; 
Ca
2+
, calcium ion.  
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1.4.3.1.3. Other molecular effects of safingol  
 
Two recent investigations shed new light that safingol could induce 
autophagic features both in in vitro and in vivo settings (127, 140). Morales et 
al showed that when safingol was given orally at 0.1% w/w of the diet to 
transgenic adenocarcinoma of mouse prostate (TRAMP) mice, 
autophagosomes were detected in the hepatocytes and no sign of increase in 
apoptosis were shown (140). Similarly, autophagic features such as the 
formation of autophagosomes, accumulation of LC3-II and increase in acidic 
vacuoles formation were demonstrated in colon cancer HCT-116 cells after 
treated with 12-18 µM safingol (127).  However, no studies have been 
performed to understand the role played by autophagy induced upon safingol 
treatment.  
 
In addition, it was demonstrated that when 25 µM of safingol was used, 
up-regulation of Bim and down-regulation of Bcl-xL resulted apoptosis in 
human oral squamous sarcoma cells (141). Interestingly, the induction of 
apoptosis was mediated by the translocation of a mitochondrial apoptotic 
factor, endonuclease G (endo-G), from mitochondria to nucleus, but not the 
activation of caspase 3 (141).  
 
1.4.3.2. Metabolism and toxicities  
 
Previously, when safingol was given at 120 mg/m
2 
in a pilot clinical 
study, it displayed a short half life of about 3.97 ± 2.51 h in plasma, with an 
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estimated clearance of 3140 ± 765 mL/min and maximum plasma 
concentration (Cmax) of 1040 ± 196 ng/mL (114). In the same study, the co-
administration of doxorubicin with safingol did not alter the pharmacokinetics 
of safingol, nor did safingol affect the pharmacokinetics of doxorubicin (114). 
This combination was found to be well-tolerated without dose-limiting 
toxicities (114). Likewise, Kedderis et al reported that no systemic toxicities 
were seen when a dose of up to 20 mg/kg safingol was administered to rats 
and dogs (122). Furthermore, when used in combination with doxorubicin, 
cisplatin or cyclophosphamide, safingol did not potentiate the drug-mediated 
toxicities. However, it is noteworthy that safingol caused intravascular 
hemolysis in rats (5 mg/kg safingol) and dogs (> 20 mg/kg safingol) (122).  
 
In view of the signs of efficacy as well as the toxicity observed, the 
question concerning the metabolic fate of safingol, thus, arises. Safingol was 
found to be preferentially N-acetylated by dihydroceramide synthase in rat 
liver microsomes to form dihydroceramide (142). Similar pattern of 
metabolism was observed in cultured baby hamster kidney cells (142), 
primary cultured neurons, neuroblastoma B104 cells, and Swiss 3T3 
fibroblasts (108). Dihyroceramide derived from safingol was then converted to 
dihydrosphingomyelin, an inactive metabolite (108). Therefore, it was 
suggested that safingol, rather than its metabolites, was responsible for its 
cytotoxic effect.  
 
In contrast, when safingol was given orally to TRAMP mice, 
hepatotoxicity and renal toxicity were observed (140). In addition to N-
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acetylated metabolites, N-methylated metabolites of safingol were detected 
(140). Although the enzymes responsible for methylation of safingol are 
unclear, it was noted that the N,N,N-trimethylsafingol was found 
predominantly in liver whereas N-methylated safingol was observed in brain 
and lung (140). When the toxicities of the metabolites of safingol were tested 
in mouse BALB 3T3 cells, N-acetylated safingol was found to be non-toxic 
whereas the mixture of N-methyl-, N,N-dimethyl- and N,N,N-trimethyl- 
safingol was only slightly less toxic than the unmodified safingol (140). Of 
note, the toxicities of the individual N-methylated metabolites have not been 
explored. 
 
1.5. Thesis Rationale and Hypothesis 
 
Till date, developing effective strategies and treatment for cancer 
patients remain a continuous challenge to the scientific and medical 
community. The ultimate goal for cancer treatment is to kill cancer cells, yet at 
the same time protecting the normal cells. Therefore, understanding how a 
drug acts and how cancer cells respond to the drug treatment, in particular the 
processes which could lead to different modes of cancer cell death, would 
open doors for the development of increasingly efficient therapeutic 
approaches. Safingol has shown promising anti-cancer activities, yet its 
underlying mechanisms remain elucidative. Therefore, the research contained 
in this thesis was designed to fill the information gaps such as the identifying 
effect of safingol in colon cancer cells, the mechanisms by which safingol 
induces cell death and its possible molecular mechanisms in synergizing with 
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other chemotherapeutic agents. The overall hypothesis is that, in addition to 
PKC inhibition, safingol could have other molecular effects when it is used 
alone and in combination with conventional chemotherapeutic agents. The 
specific objectives for this thesis are listed as follow:  
 
1) To investigate the role of PKC in modulating the effect of safingol and 
its combination with irinotecan in colon cancer cells. This is described in 
Chapter 3, where the synergistic effects, in terms of cell killing, PKC 
expression and its downstream effects, between safingol and irinotecan were 
explored in colon cancer cells.   
 
2) To explore the role of ROS and autophagy in safingol-treated cancer 
cells. This is described in Chapter 4, where a series of experiments were 
performed to identify the mode of cell death induced by safingol, and whether 
ROS and autophagy mediate safingol-induced cell death.   
 
3) To evaluate the effects of ROS in safingol-based combinations in 
various cancer cell lines. This is described in Chapter 5, where the synergistic 
effect, in terms of cell-killing, between safingol and apoptotic and ROS-
generating chemotherapeutic agents was examined.  
 
The final chapter of this thesis (Chapter 6) covers an overall discussion and 
conclusions drawn from these studies, highlighting the areas of particular 
interest for future investigations.  
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Chapter 2: Material and Methods  
 
2.1. Materials  
 
2.1.1. Reagents  
 
Safingol was purchased from Sigma (St.Louis, MO, USA) and 
dissolved in ethanol. Stock solutions of 2 mg/mL were stored in the freezer at 
-20°C and freshly diluted with medium to the appropriate concentrations 
before used in experiments. Irinotecan hydrochloride trihydrate 20 mg/mL 
(Aventis Pharma, United Kingdom), 5-fluorouracil (5-FU) 50 mg/mL (Mayne 
Pharma, Australia), doxorubicin hydrochloride 2 mg/mL (Pfizer, Bentley WA, 
Australia), gemcitabine 40 mg/mL (Lilly France SAS, France), vincristine 1 
mg/mL (Sigma, St.Louis, MO, USA), carboplatin 10 mg/mL (Pharmachemie 
BV, The Netherlands) were purchased from the National University Hospital, 
Singapore. All other chemicals used in the study were purchased from Sigma 
Chemical Company unless otherwise stated.  
 
2.1.2. Cell Lines 
 
Human breast cancer cell lines (MDA-MB-231, JIMT-1), ovarian 
cancer cell line (SKOV-3), colorectal cancer cell lines (LS-174T, HT-29), 
leukemic cell lines (U937) and nasopharynx cell line (KB) were purchased 
from American Type Culture Collection (Manassas, USA). Stock cultures of 
all cancer cell lines were maintained as monolayer in 75-cm
2
 tissue culture 
flasks (Iwaki, Japan). MDA-MB-231 and U937 cells were cultured in Roswell 
 50 
Park Memorial Institute 1640 (RPMI 1640) medium; JIMT-1 in Dulbecco’s 
Modified Eagle’s Medium F12 (DMEM F12); SKOV-3 in McCoy 5A medium; 
LS-174T in Dulbecco’s Modified Eagle’s Medium (DMEM); HT-29 in 
Iscove’s Modified Dulbecco’s Medium (IMDM). All media were 
supplemented with 10% v/v fetal bovine serum (FBS; HyClone Laboratories, 
Logan, UT, USA), 0.3 g/L L-glutamine, 100 U/mL
 
penicillin and 100 µg/mL 
streptomycin. All cell lines were maintained in a humidified, 5% CO2 
incubator at 37°C and sub-cultured twice weekly using 0.25% v/v 
trypsin/EDTA (GIBCO, Grand Island, NY, USA).  All experiments were 
performed using cells in exponential growth phase from passage 5 to 20 post-
thawing from frozen stock. 
 
2.1.3. Antibodies   
 
Primary rabbit polyclonal p-PKC (pan) (γThr514), p-MARCKS 
(Ser152/156), p-AMPK (Thr172), p-mTOR (Ser2448), LC3-II, beclin-1, Atg 5, 
Atg 7, Atg 12, Bcl-xL, Bax and mouse monoclonal β-actin antibodies were 
purchased from Cell Signaling Technology, Inc (Danvers, MA, USA). 
Secondary goat anti-rabbit and anti-mouse antibodies were purchased from 
Pierce Biotechnology (Rockford, IL, USA).  
 
2.2. Cell viability assay 
 
Viability of the cancer cells following drug treatments was determined 
using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay, which tests the reductive capacity of dehydrogenases 
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present only in metabolically active cells.  In brief, cells were plated at 5,000 
cells per well in 96-well plates and allowed to adhere overnight before 
exposure to safingol or various drugs/agents. The plates were then incubated 
for specified period of time (refer to figure legends). At the end of the 
incubation, 50 µL MTT (1 mg/mL in media) was added to cells and incubated 
for 4 h.  Subsequently, the MTT-containing medium was removed, and the 
purple formazan precipitate was solubilized in 150 µL dimethyl sulphoxide 
(DMSO) with shaking.  Absorbance (Abs) reading (λ = 570 nm) was then 
measured using a microtiter plate reader (Tecan, Infinite M2000). All assays 
were done at least three times unless otherwise stated.  
 
 Cancer cell viability was calculated based on the absorbance readings 
using the following equation: viability = [(Abstest – Absblank) / (Absvehicle control – 
Absblank)] × 100%, where Abstest, Absblank, Absvehicle control represent the 
absorbance readings from the drug-treated wells, the medium only wells and 
the vehicle control wells, respectively.  Using the median effect principle 
described by Chou and Talalay (117), the potency of the drugs could be 
reflected by the median dose (Dm) values which were estimated using 
CalcuSyn 3.0 software (Biosoft, Cambridge, UK). With respect to drug 
combination experiments, results obtained from the MTT assay were used to 
compute the CI using the following equation, with the assumption that the 
drug combinations were mutually exclusive: CI = [(D)1 / (Dx)1] + [(D)2 / (Dx)2], 
where (D)1 and (D)2 are the concentrations of drug 1 and drug 2, respectively, 
that inhibit x% in the actual experiment when they are used in combination.  
(Dx)1 and (Dx)2 are the concentrations of drug 1 and drug 2, respectively, that 
 52 
inhibit x% in the actual experiment when they are used as single agents.  
Having a CI of less than 1, equals to 1 or more than 1 is indicative of a 
synergistic, additive or antagonistic interaction for a drug combination, 
respectively. 
 
2.3. Flow Cytometry  
 
2.3.1. Propidium iodide staining  
 
Flow cytometric analysis was performed to determine the distribution 
of cells in the various phases of the cell cycle using propidium iodide (PI) to 
stain for nuclear DNA.  1.5×10
6 
cells were seeded in T-75 flasks and treated 
with safingol alone or in combination with drugs for 24 h and 48 h. After 
drugs treatment, 1×10
6
 cells were harvested, washed with ice-cold phosphate-
buffered saline (PBS), fixed with ice-cold 70% v/v ethanol overnight at −20°C 
followed by staining with PI staining buffer (1 mg/mL RNase A, 0.1% v/v 
Triton X-100, 50 µg/mL PI in PBS) at 37°C for 15 min. The samples were 
subsequently incubated on ice for 1 h before analysis.  Stained samples were 
analyzed on the Dako flow cytometer (CyAn™ ADP), and 10,000 events were 
collected.  Data were plotted with Summit V4.3 Build 2445 software. The 






2.3.2. Annexin V-FITC/7AAD staining  
 
In brief, 1.5 ×10
6
 cells were seeded and treated with 2, 5 or 10 µM 
safingol with and without 10 mM N-acetyl-L-cysteine (NAC) in MDA-MB-
231 or 2.5 mM NAC in HT-29 for 48 h. 2% paraformaldehyde was used as a 
positive control for inducing necrotic cell death. After drug exposure, cells 
were harvested, washed with ice-cold PBS, and stained with Annexin V-FITC/ 
7AAD kit (Beckman Coulter, France) for 15 mins in dark. 450 µL of binding 
buffer were then added to terminate the reaction. The samples were kept on ice 
before subjected to flow cytometric analysis. Stained samples were analyzed 
on the Dako flow cytometer (CyAn™ ADP), and 10,000 events were collected.  
Data were plotted with Summit V4.3 Build 2445 software. 
 
2.4. Protein analysis by Western blot 
 
Cells were exposed to safingol or other drugs for the specified 
concentrations and durations (refer to figure legends). After drug treatment, 
cells were washed with ice-cold PBS, harvested by trypsinization and lysed in 
ice-cold cell lysis buffer [20 mM Tris pH 7.5, 150 mM NaCl, 10 mM EDTA, 
1% w/v NP-40, 20 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM 
sodium vanadate, 10% v/v glycerol, 1X protease inhibitor cocktail (just added 
before use)].  Protein concentrations were determined using the Bio-rad 
Protein Assay Kit (Biorad Laboratories, Hercules, CA) according to the 
manufacturer’s instructions.  Proteins were separated by electrophoresis 
carried out on 1.5-mm thick, 6-12% sodium dodecyl sulfate-polyacrylamide 
gels using Biorad’s Powerpac™ HC Apparatus (Bio-Rad Laboratories, 
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Singapore) and electroblotted onto nitrocellulose membranes in ice-cold 
transfer buffer (39 mM glycine, 48 mM Tris base, 20% v/v methanol).  The 
membranes were subsequently blocked with 5% w/v bovine serum albumin 
(BSA; Sigma-Aldrich, St. Louis, MO, USA) in Tris-buffered saline with 0.1% 
v/v Tween 20 (TBS/T) for at least 2 h. After blocking, the membranes were 
probed with primary antibodies overnight at 4°C. Primary antibodies were 
diluted with TBS/T in 1:1000 ratio containing 5% w/v BSA. Subsequently, 
membranes were washed three times with TBS/T before probed with 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (Pierce 
Biotechnology, Rockford, IL, USA) for another hour, followed by detection 
with chemi-luminescence Supersignal® West Dura Extended Duration 
Substrate (Pierce Biotechnology, Rockford, IL, USA). Protein bands were 
then visualized by CL-Xposure film (Thermo Scientific). For reprobing, blots 
were stripped with Restore Western Blot stripping buffer (Thermo Scientific). 
β-actin was included as the loading control.  
 
2.5. Cell adhesion assay 
 
In brief, cells were plated at 6 × 10
5
 cells per well in 6-well plates and 
allowed to adhere overnight. Two wells per treatment group were used. On the 
next day, cells were exposed to safingol, irinotecan or combinations of 
safingol/irinotecan at 1:1 molar ratio for 4 h in serum-free media. At the end 
of the drug treatments, equal number of viable cells (7 × 10
5
 cells) was seeded 
onto a 24-well plate which was pre-coated with basement membrane matrix 
gel (BD Biosciences, MA) and allowed to attach for 24 h at 37°C. At the end 
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of the incubation, media was aspirated and the cells were washed thrice with 
PBS to remove non-adherent cells. The morphology of attached cells was 
photographed using Leica light microscope. Lastly, 400 µL of premixed WST-
1 cell proliferation reagent (Clontech Laboratories, Inc) was added and 
absorbance was measured at 440 nm. Percentage of cell adhesion was 
calculated using the following equation: % cell adhesion = (Abstest / Absvehicle 
control ) × 100%, where Abstest and Absvehicle control represent the absorbance 
readings from drug-treated and the vehicle control wells, respectively.  
 
2.6. Electron microscopy 
 
Cells were seeded at 4 × 10
5
 cells in T-175 flasks. MDA-MB-231 and 
HT-29 cells were treated with safingol at 5 µM and 10 µM, respectively for 24 
h.  After safingol treatment, cells were harvested by trypsinization, washed 
twice with PBS and pre-fixed with ice-cold 2.5% v/v glutaraldehyde and 2% 
v/v paraformaldehyde in sodium/potassium phosphate buffer (pH 7.18) for 3 h. 
After washing thrice with PBS, cells were post-fixed in 1% w/v osmium 
tetroxide in dark for 2 h. Subsequently, cells were dehydrated by immersing 
them in a sequence of increasing concentrations of ethanol [30%, 50%, 70%, 
80%, 90%, 95% (2 changes) and 100% (2 changes)] for 15 mins each. Then, 
the cells were further dehydrated with 1:1 mixture of ethanol: propylene oxide 
for 20 mins, followed by 100% propylene oxide for 30 mins (2 changes) and 
finally in 1:1 mixture of propylene oxide: Spurr’s resin for 30 mins (2 
changes). Lastly, cells were embedded in Spurr’s resin at 80ºC until hardened. 
90 nm thin sections were cut, stained with Hiraoka staining kit (uranyl acetate 
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and lead nitrate) and viewed with PHILIPS CM10 transmission electron 
microscope. 
 




 cells were seeded at in T-75 flasks and treated for 8, 24 and 
48 h with 10 µM safingol. Then, 1 × 10
5
 cells were harvested by trypsinization 
and incubated with 100 µL 5,5’,6,6’ tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1) at a final concentration of 
1 µg/mL for 30 mins at 37°C. In healthy cells, JC-1 stains the mitochondria 
red whereas in cells with collapsed mitochondria membrane potential (MMP), 
JC-1 remains in the cytoplasm and emits green fluorescence. After staining, 
cells were washed twice with ice-cold PBS and subjected to flow cytometry 
analysis using Dako flow cytometer (CyAn™ ADP), and 10,000 events were 
collected. Data were plotted with Summit V4.3 Build 2445 software. 
 




cells per well were plated in black 96-well plates and allowed 
to adhere overnight. Following 48 h treatment with 2, 5 and 10 µM safingol, 
ATP levels were measured using the ATP bioluminescence assay kit HSII 





M diluted with dilution buffer provided in the kit. 50 µL 
of cell lysis reagent provided in the kit was added to drug-treated cells and 
ATP standard for 5 min at room temperature. Then, 50 µL of sample or 
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standard was transferred to a black 96-well plate with 50 µL of luciferase 
added to the samples and standard. Luciferase catalyses the following reaction:  
ATP + D-luciferin + O2 →oxyluciferin + PPi +AMP + CO2 + light 
Light emission is linearly related to the concentration of ATP. Luminescence 
was then measured using a microplate reader (Tecan, Infinite 2000). 
Measurements were made after 1 sec of shaking and with integration time of 
10 sec. ATP concentrations were calculated after subtracting the blank from 
the raw data and a log-log plot of the standard curve were plotted. 
 
2.9. ROS detection assay 
 
ROS measurement was performed using 2’,7’-
dichlorodihydrofluorescein diacetate (H2DCFDA) according to manufacturer’s 
instructions. In brief, each 96-well plates was seeded with 2 × 10
4  
cells per 
well and allowed to adhere overnight. 2, 5 and 10 µM safingol was added for 
the indicated period. H2O2 was used as a positive control. Following the drug 
treatment, media was removed and cells were loaded with 5 µM H2DCFDA 
diluted in clear media for 30 mins at 37°C. Cells were washed thrice with clear 
media and fluorescence intensity (excitation = 485 nm; emission = 530 nm) 
was measured using a microtiter plate reader (Tecan, Infinite M2000). 
Morphology of cells was photographed using Nikon ECLIPSE TE2000-U 
microscope. Lastly, 100 µL of premixed WST-1 cell proliferation reagent 
(Clontech Laboratories, Inc, USA) was added to determine the cell viability. 
Abs was measured at λ= 440 nm in a microplate reader (Tecan, Infinite 2000). 
Folds increased in ROS production was calculated using the following 
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equation: (Ftest – Fblank) / (Fcontrol – Fblank), where Ftest, Fblank, Fcontrol represent 
the fluorescence readings from the drug-treated wells, the unstained cells and 
the stained control wells, respectively. 
 
2.10. Acridine orange staining 
 
Each 96-well plates was seeded with 2 × 10
5  
cells per well and allowed 
to adhere overnight. Safingol with or without 3-methyladenine (3-MA)/ NAC/ 
gossypol were added for the indicated period. Staining of cells with acridine 
orange was performed according to published procedures (40). Acridine 
orange at a final concentration of 1 mg/mL was added to treated-cells for a 
period of 20 mins at 37°C.  Then, cells were washed twice with PBS. Images 
of cells were obtained using Nikon ECLIPSE TE2000-U microscope.  
 
2.11. Glucose uptake assay 
 
Cells were plated at 2 × 10
4  
cells per well in 96-well plates and 
allowed to adhere overnight. On the following day, cell culture medium was 
removed and replaced by glucose-free medium for 24 h. Then, safingol at 10 
µM was added to cells for 2 and 4 h. At the end of safingol treatment, 0.3 mM 
of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) 
(Invitrogen, Oregon, USA)  diluted in Hanks-buffered salt solution (HBSS) 
was added into each well for 30 mins at 37°C. The 2-NBDG uptake reaction 
was stopped by removing the medium and washing the cells twice with HBSS. 
Images of cells were obtained using Olympus FluoView FV300 microscope. 
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2.12. Statistical analysis 
 
All data values were reported as mean ± standard error of the mean 
(SEM). Statistical differences were determined using the Student t-test or one-
way analysis of variance (ANOVA) with Dunnett’s test used for post-hoc 




Chapter 3: The role of protein kinase C in the synergistic 
interaction of safingol and irinotecan in colon cancer cells




As described in Chapter 1, colon cancer is one of the most frequently 
diagnosed cancers in Singapore, and it is a leading cause of cancer-related 
mortality worldwide (144). Anti-cancer drugs such as irinotecan and 5-
fluorouracil (5-FU) have been routinely administered, often with curative 
intent, to eradicate circulating cancer cells. Irinotecan is a topoisomerase I 
inhibitor, whereby inhibition of this enzyme results in stabilization of the 
cleavable complex, breakage of DNA strands, failure of replication and 
ultimately cell death (145-147). 5-FU inhibits thymidylate synthase, an 
enzyme essential for the synthesis of pyrimidines required for DNA 
replication (148). Nevertheless, response rates of colon cancer patients treated 
with these two standard cytotoxic drugs remain <40% when these drugs are 
used as monotherapies, with patients subsequently becoming resistant (149, 
150).  Therefore, it is imperative to identify other drugs or drugs combinations, 
especially those which can target particular signaling pathways to provide 
alternative therapeutic options to effectively eliminate the cancer cells and 
improve the survival of colon cancer patients. 
 
                                                 
1 Adapted from: L.U Ling, H. Lin, K.B. Tan and Gigi C.N. Chiu. The role of protein kinase C 
in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J of Oncology, 
35: 1463-1471, 2009.  
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As discussed in Chapter 1, safingol has shown effective anti-cancer 
activities when used in combination with chemotherapies in a variety of 
cancer cells (109, 114, 116-120, 151). While safingol has been previously 
shown to potentiate the anti-cancer effect of irinotecan in colon cancer cells 
(149), the molecular mechanism underlying the potentiating effect has not 
been explored. Since the PKC pathway plays an important role in colon cancer 
cell proliferation, adhesion and migration (152, 153), it is hypothesized that 
the enhanced cancer cell kill by a combination of safingol and irinotecan could 
be mediated through the PKC pathway.  This chapter is focused on probing the 
changes in the expression levels of phosphorylated PKC and its downstream 
substrate, myristoylated alanine-rich C-kinase substrate (MARCKS), as well 
as the ability of colon cancer cells to attach to extracellular matrix upon 
exposure to safingol/irinotecan combination.  In addition, the drug effect of 
this combination in the presence of modulators of PKC activity is analyzed 
using the median effect principle described by Chou and Talalay (10) to give a 
quantitative representation of the pharmacological interaction between 












3.2.1. Effect of safingol, irinotecan or 5-FU as single agents in colon 
cancer cells 
 
The biological effect of safingol on HT-29 and LS-174T colon cancer 
cell lines was compared to that of irinotecan and 5-FU, the two cytotoxic 
drugs commonly used in colon cancer therapy. Cell viability was determined 
using MTT assay.  After drug exposure of 72 h, the viability of HT-29 and LS-
174T cells was reduced by safingol, irinotecan and 5-FU in a concentration-
dependent manner (Figure 3.1).  In order to compare the potency of safingol, 
irinotecan and 5-FU in the two cell lines, the IC50 value of each drug in the 
respective cell line was estimated and summarized in Table 3.1.  Among the 
three drugs, the IC50 values for safingol were the lowest, with 2.5 ± 1.1 µM 
and 3.4 ± 1.0 µM achieved in HT-29 and LS-174T cells, respectively. This 
translates to a 5.6-fold and a 2.1-fold improvement in potency in HT-29 and 
LS-174T cells, respectively, when safingol activity was compared to that of 
irinotecan. Similarly, a 9.2-fold and a 10-fold improvement in potency was 
observed in HT-29 and LS-174T cells, respectively, when safingol activity 
was compared to that of 5-FU. Of note, these IC50 values of safingol could be 
















































Figure 3.1 Effect of safingol (■), irinotecan (▲) or 5-FU (●) on the 
viability of HT-29 and LS-174T cells. Cells were treated with the indicated 
concentrations of drugs for 72 h. Cellular viability was assessed using MTT 









Cell Line Safingol (µM) Irinotecan (µM) 5-FU (µM) 
HT-29         2.5 ± 1.1 14 ± 2.5* 23 ± 7.3* 
LS-174T         3.4 ± 1.0                           7.3 ± 2.3*     35 ± 13* 
Cell viability was determined using MTT assay and subsequently analyzed by Calcusyn 
3.0 software to estimate IC50 values. Each reported value is the mean ± SEM from three 
independent experiments. All r values, which represent the linear correlation coefficient of 
the median-effect plot, were ≥ 0.9. * p<0.05, significantly different from safingol-treated 
group.  
Table 3.1 IC50 values of safingol, irinotecan and 5-FU in HT-29 and LS-
174T colon cancer cell lines. 
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3.2.2. Effect of fixed ratio combinations of safingol and irinotecan 
 
As irinotecan showed relatively poor treatment response rates when 
administered as a single agent, it has been combined with safingol previously, 
using specific concentrations of the two agents in an attempt to enhance the 
anti-cancer effect (149).  As described in Chapter 1, ratios of individual agents 
could influence the therapeutic outcome. Therefore, in this study, fixed molar 
ratio combinations of safingol and irinotecan were evaluated over a range of 
concentrations, and specifically, the two drugs were administered at molar 
ratios of 4:1, 1:1 and 1:4.  The measure of synergy between the two drugs was 
determined by the CI value derived from the median effect principle described 
by Chou and Talalay using the software CalcuSyn 3.0 (10).  The plots of CI 
against fraction affected (Fa) for the various fixed ratio combinations of 
safingol/irinotecan in HT-29 and LS-174T cells were presented in Figure 3.2. 
It is important to evaluate if the drug combination is synergistic at maximum 
cancer cell kill; thus, the CI values were estimated at an effect level of 90% 
cell kill for the various ratios and were summarized in Table 3.2.  The 1:1 
molar ratio of safingol/irinotecan appeared to be the most promising, with a CI 
value of 0.68 in LS-174T cells indicating synergy and a CI value of 0.94 in 
HT-29 cells indicating additivity. Furthermore, safingol/irinotecan at 1:1 
molar ratio allowed substantial dose reduction when used in combination as 
compared to the administration of the individual agents.  Specifically, the 
concentrations to achieve 90% cell kill in HT-29 and LS-174T cells for 









































































































































Figure 3.2 Effect of fixed ratio combinations of safingol and irinotecan in HT-
29 and LS-174T cells. (A) Combination index was plotted as a function of 
fraction affected for safingol/irinotecan at 1:1 (■), 1:4 (▲) and 4:1 (●) molar 
ratio in the colon cancer cell lines. Cell viability was assessed using MTT assay 
and effective concentrations were analyzed using Calcusyn 3.0 software. CI 
value of < 1 is synergistic, ~1 is additive and > 1 is antagonistic. (B) The drug 
concentrations required to achieve 90% cell kill of safingol (clear bars) and 




Combination Index (CI) Combination 
LS-174T HT-29 
Safingol / Irinotecan  
4:1 1.9 0.99 
1:1 0.68 0.94 
1:4 5.6  1.3 
Table 3.2 Combination indices of safingol/irinotecan combinations administered 
in different fixed molar ratios in colon cancer cell lines.  
Results from MTT viability assay were pooled from three independent studies and used to 
compute the CI values using Calcusyn 3.0 software. The reported CI values were based on the 
drug concentration to achieve 90% cell kill. CI <1, ~1 or >1 denotes a synergistic, additive or 
antagonistic interaction of the combination, respectively. All r values, which represent the 
linear correlation coefficient of the median-effect plot, were ≥ 0.9. 
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safingol were reduced by 1.5-fold in both of the cell lines (Figure 3.2). On the 
contrary, safingol/irinotecan at 1:4 molar ratio showed strong antagonism in 
both cell lines, and the combination at 4:1 molar ratio showed antagonism in 
LS-174T cells and additive effect in HT-29 cells. These results are not 
unexpected as treatment outcome of drug combinations could be highly 
dependent on the ratios of the individual agents (9). 
 
3.2.3. Effect of safingol/irinotecan at 1:1 molar ratio on the cell cycle 
status of colon cancer cells 
 
Propidium iodide staining was performed on cells treated with safingol 
or irinotecan alone or the drug combination, and the results are presented in 
Table 3.3 and 3.4. Three observations could be made.  First, as the exposure 
time was increased from 24 h to 48 h, treatments with either the individual 
drugs (10 µM safingol or 10 µM irinotecan) or the combination (10 µM 
safingol+10 µM irinotecan) exhibited increases in the percentage in the sub-
G1/G0 phase.  Second, it is of note that the cell cycle profiles of irinotecan-
treated cells were different from those of safingol-treated cells. Irinotecan 
induced significant increases in the percentage of cells in the G2/M phase, 
which is consistent with previous findings (154, 155), whereas safingol 
induced significant increases in the sub-G1/G0 fraction without significantly 
affecting G2/M phase. These results suggest that safingol and irinotecan acted 
differently on the cell cycle and in the induction of cell death. Third, 




24 h treatment sub-G1/G0 G1 S G2/M 
Control  1.73 ± 0.1% 50.7 ± 1.48% 26.0 ± 2.92% 22.1 ± 1.76% 
10 µM Safingol 7.65 ± 1.31%* 37.3 ± 2.65%* 19.9 ± 3.62% 35.7 ± 3.65% 
10 µM Irinotecan 2.11 ± 0.37% 4.91 ± 0.23%* 39.9 ± 12.3% 53.8 ± 12.3%* 
Saf/Irinotecan (1:1) 10.9 ± 1.71%* 13.8 ± 1.69%* 27.6 ± 2.57% 48.4 ± 3.14% 
48 h treatment sub-G1/G0 G1 S G2/M 
Control  2.24 ± 0.16% 56.9 ± 4.20% 23.4 ± 4.67% 18.1 ± 0.79% 
10 µM Safingol 14.3 ± 0.35%* 38.6 ± 2.63%* 19.6 ± 1.43% 28.3 ± 3.20% 
10 µM Irinotecan 
Saf/Irinotecan (1:1) 
13.2± 2.85%* 
23.2 ± 3.99%* 
7.19 ± 0.69%* 
17.7 ± 0.74%* 
19.3 ± 4.43% 
28.6 ± 1.25% 
49.2 ± 12.5%* 
31.0 ± 2.36% 
Table 3.3 Percentage of HT-29 cells in various phases of the cell cycle after 
treated with safingol, irinotecan or safingol/irinotecan (1:1) for 24 h and 48 h. 
Each reported value represents the mean ± SEM from three independent experiments. 




24 h treatment sub-G1/G0 G1 S G2/M 
Control 4.74 ± 0.25% 65.4 ± 2.72% 17.7 ± 1.99% 12.8 ± 0.74% 
10 µM Safingol 32.7 ± 7.09%* 43.5 ± 5.72%* 12.3 ± 0.18% 12.0 ± 1.32% 
10 µM Irinotecan 5.57 ± 1.17% 18.4 ± 1.65%* 28.9 ± 5.14%* 47.8 ± 4.46%* 
Saf/Irinotecan (1:1) 38.6 ± 4.02%* 22.4 ± 1.90%* 17.2 ± 0.49% 22.0 ± 2.76% 
48 h treatment sub-G1/G0 G1 S G2/M 
Control 8.84 ± 1.81% 65.4 ± 1.94% 14.5 ± 1.29% 11.0 ± 2.30% 
10 µM Safingol 41.8 ± 7.03%* 39.1 ± 4.45%* 11.5 ± 0.67% 6.35 ± 2.14% 
10 µM Irinotecan 9.87 ± 0.88% 18.0 ± 1.85%* 32.3 ± 4.25%* 37.6 ± 3.81%* 
Saf/Irinotecan (1:1) 57.7 ± 3.24%* 18.8 ± 2.03%* 12.1 ± 0.39% 14.3 ± 3.36% 
Each reported value represents the mean ± SEM from three independent experiments. 
*p<0.05, significantly different from control group. 
Table 3.4 Percentage of LS-174T cells in various phases of the cell cycle after 
treated with safingol, irinotecan or safingol/irinotecan (1:1) for 24 h and 48 h. 
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ratio of the drug combination, the results indicated that the effect of the 1:1 
safingol/irinotecan combination was additive in HT-29 cells and supra-
additive in LS-174T cells. These observations are consistent with the cell 
viability data presented in Figure 3.1. 
 
3.2.4. Role of PKC in mediating the cytotoxic effect of safingol and 
safingol/irinotecan combination 
 
Since the PKC pathway plays an important role in colon cancer cell 
proliferation, adhesion and migration (152, 153), it is of interest to investigate 
the role of PKC in mediating the cytotoxic effect of the safingol/irinotecan 
combination.  The expression levels of phosphorylated PKC and its 
downstream substrate, MARCKS (120), were probed by immunoblotting after 
treatment with safingol or irinotecan alone or the drug combination at 1:1 
molar ratio (Figure 3.3).  Unexpectedly, the expression levels of p-PKC and 
p-MARCKS in HT-29 and LS-174T cells were only slightly reduced by 10 
µM safingol after 72 h of exposure (Figure 3.3A), despite the finding that 
safingol is a PKC inhibitor which binds to the regulatory domain of the kinase 
(122, 128). While substantial cell kill could be achieved with 10 µM safingol 
(Figure 3.1, Table 3.3 and 3.4), this effect may not be mediated through 
modulation of PKC activity. On the contrary, safingol/irinotecan at 1:1 molar 
ratio substantially reduced the expression levels of p-PKC and p-MARCKS in 
HT-29 and LS-174T cells (Figure 3.3A).  Furthermore, the reduction of p-
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Figure 3.3 The effect of safingol, irinotecan or safingol/irinotecan (1:1) on the 
phosphorylation of PKC and MARCKS in HT-29 and LS-174T cells. Protein 
lysates were assayed by Western blotting and β-actin was used as the loading 
control. (A) HT-29 and LS-174T cells were treated with 10 µM safingol, 10 
µM irinotecan or 10 µM safingol+10 µM irinotecan (1:1 molar ratio) for 72 h. 
(B) Concentration-dependent down-regulation of p-PKC and p-MARCKS. 
Values indicated in this panel represent the molar concentrations (in µM) of 
safingol and irinotecan when given at 1:1 ratio. (C) Time-dependent down-
regulation of p-PKC and p-MARCKS. The concentration of safingol and 
irinotecan used in the 1:1 combination was 10 µM for each drug. All blots 
shown are representative of three independent experiments.  
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concentration of the drug combination (Figure 3.3B) and the exposure time 
(Figure 3.3C). 
 
To further investigate the role of PKC in the synergistic effect of 1:1 
safingol/irinotecan combination, modulators of PKC activity were used on LS-
174T cells, which included the stimulator phorbol 12-myristate 13-acetate 
(PMA) (156) and the inhibitor staurosporine (157).  Treatment with safingol 
alone or irinotecan alone provided modest reduction of p-PKC and p-
MARCKS expression levels when the colon cancer cells were stimulated with 
PMA (Figure 3.4A).  In contrast, treatment with the 1:1 safingol/irinotecan 
combination reduced substantially the phosphorylation of PKC and of 
MARCKS.  Cell viability in the presence of PMA stimulation was determined 
for various drug treatments, and CI values were determined based on the 
viability data.  In LS-174T cells, the CI value for the combination was reduced 
from 0.68 (no PMA) to 0.48 (with PMA), indicating an increase in synergism 
under PKC stimulation (Figure 3.4B).  In contrast, the presence of 50 nM 
staurosporine, which was effective in inhibiting PKC activity, could modulate 
the outcome of the 1:1 safingol/irinotecan combination from a synergistic 
effect to an antagonistic effect, as reflected by the increase in CI value from 
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Figure 3.4 Effect of safingol, irinotecan or safingol/irinotecan (1:1) with or 
without PMA and staurosporine in LS-174T cells. (A) Phosphorylation of 
PKC and MARCKS with or without PMA stimulation. Protein lysates were 
assayed by Western blotting and β-actin was used as the loading control. 
All blots shown are representative of three independent experiments.  (B) 
Combination index at 90% cell kill of safingol/irinotecan (1:1) with (filled 
bars) or without (clear bars) PMA stimulation. (C) Combination index at 
90% cell kill of safingol/irinotecan (1:1) with (filled bars) or without (clear 
bars) staurosporine. Cell viability was assessed using MTT assay and 
effective concentrations were used to compute the combination indices 
using Calcusyn 3.0 software. CI value of < 1 is synergistic, =1 is additive 
and > 1 is antagonistic.  
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3.2.5. Effect of safingol/irinotecan at 1:1 molar ratio on colon cancer cell 
adhesion 
 
As activation of PKC is reported to mediate cell adhesion and 
migration (123, 152, 158), the effect of the 1:1 safingol/irinotecan 
combination on inhibiting colon cancer cell adhesion to extracellular matrix 
was investigated using a Matrigel-based in vitro assay. After 4 h of treatment 
with the 1:1 safingol/irinotecan combination and cells were allowed to adhere 
to Matrigel for 24 h, significant decreases in the percentage of HT-29 and LS-
174T cells adhered to the Matrigel could be observed (Figure 3.5).  This 
observation is consistent with the ability of the drug combination to modulate 




Figure 3.5 Effect of safingol, irinotecan or safingol/irinotecan (1:1) on cell 
adhesion in HT-29 and LS-174T cells. (A) Cells were treated with 10 µM 
safingol, 10 µM irinotecan or 10 µM safingol + 10 µM irinotecan (1:1 
molar ratio) for 4 h and allowed to adhere to Matrigel for 24 h. Number of 
cells adhered were determined using WST-1 cell proliferation reagent. 
Each reported value represents the mean ± SEM from three independent 
experiments. * represents p<0.05, where safingol/irinotecan was 
significantly different from other groups. (B) Representative images of 
cells taken under a light microscope. a) control, b) 10 µM safingol, c) 10 
µM irinotecan, d) 10 µM safingol + 10 µM irinotecan (1:1 molar ratio). 
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In the present study, the anti-cancer activity of safingol as a single 
agent was compared to that of two commonly used chemotherapeutic drugs, 
irinotecan and 5-FU, in the colon cancer cell lines, HT-29 and LS-174T.  The 
results in this chapter demonstrated that safingol as a single agent was more 
potent than irinotecan or 5-FU monotherapy.  However, from a clinical point 
of view, combinations of chemotherapeutics are often used to treat cancer 
patients to reduce the risk of developing resistance.  If a particular anti-cancer 
drug combination is synergistic, it would further offer the benefit of reducing 
the dose and subsequent treatment-related toxicities, yet without 
compromising efficacy. Indeed, safingol is being evaluated not as 
monotherapy but in combination with cisplatin in a Phase I clinical trial for 
treating solid tumors (115). Thus, in this study, safingol was combined with 
irinotecan in various fixed molar ratios to determine if this drug combination 
was synergistic in colon cancer.   
 
As compared to previous studies that have reported the role of safingol 
as a PKC inhibitor (120, 122, 128), the results obtained in this chapter 
demonstrated only modest inhibitory effect on PKC and MARCKS 
phosphorylation when colon cancer cells were exposed to 10 µM safingol. 
However, substantial cell kill could be observed in the current study at this 
concentration of safingol, as demonstrated by MTT viability data and flow 
cytometry analyses.  It is possible that exposure to high concentrations of 
safingol (40 – 50 µM) could lead to effective inhibition of PKC activity and 
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phosphorylation of MARCKS (120, 126), and that safingol could have 
inhibited PKC without interfering its phosphorylation site (120). The current 
results, on the other hand, are comparable with those reported by Hoffmann et 
al (117), whereby the IC50 values of safingol in six cell lines of squamous cell 
carcinomas of head and neck ranged from 3.8 – 8.6 µM, similar to those 
obtained here.  More importantly, previously reported serum levels of safingol 
that could be achieved in human (Cmax of 3.44 µM) compared well with the in 
vitro concentrations used here (114).  Thus, the current data suggest that PKC 
inhibition may not be the primary molecular effect of safingol monotherapy, 
which is in line with observations from Hoffmann et al that no relationship 
existed between PKC activity and sensitivity to safingol in squamous cell 
carcinomas of head and neck (117).  However, subtle differences in the 
sensitivity to safingol among the individual PKC isoforms might be possible.  
More recent reports have shed new lights onto the molecular mechanism of 
safingol, which could act as an inhibitor of SK (115) or as an inducer of 
autophagy (127).  Further studies on the molecular effects brought about by 
safingol would contribute to the selection of appropriate anti-cancer agents for 
effective combination treatment strategies, and this forms the basis for 
Chapters 4 and 5. 
 
Protein kinase C has emerged as an important target for anti-cancer 
drug development, and numerous small molecule inhibitors and anti-sense 
molecules have been developed and entered into clinical trials (159-161). 
Given the important role of PKC in tumorigenesis, cell proliferation, and drug 
resistance development, it is of interest to explore the role of PKC in 
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mediating the synergistic effect of safingol/irinotecan combination given at 
1:1 molar ratio.  This combination effectively inhibited the phosphorylation of 
PKC and MARCKS in a concentration- and time-dependent manner, 
suggesting that the inhibition of PKC pathway could be responsible for the 
synergism of the safingol/irinotecan combination.  Moreover, the drug 
combination effect could be further modulated by the use of either a PKC 
stimulator or a PKC inhibitor.  The drug combination could also inhibit cell 
adhesion to extracellular matrix. This is important because the ability of 
cancer cells to extravasate and intravasate is greatly controlled by their 
attachment to basement membrane and extracellular matrix (162). A recent 
report by Noda et al (141) showed that 25-30% of oral squamous cell 
carcinoma cells were unable to adhere to growth surface after treated with 25 
µM safingol for 3-6 hours. In the current study, with a 4-hour treatment of 
safingol/irinotecan 1:1 combination (at 10 µM for each drug), 40-55% of 
colon cancer cells were unable to adhere to the extracellular matrix. This 
finding suggests the potential of the safingol/irinotecan drug combination in 
preventing tumor cell adhesion and subsequently invasion and metastasis. 
   
More importantly, the concentrations of safingol and irinotecan used in 
the current study to effect synergism in killing colon cancer cells could be 
achieved clinically.  One of the key advantages in using synergistic drug 
combinations is the potential to minimize toxicities from the individual drugs, 
and it is also desirable if the toxicities of the individual drugs are non-
overlapping.  The primary toxicity of safingol in human/animals are 
intravascular hemolysis and hepatotoxicity (122, 140), whereas the dose-
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limiting toxic effect of irinotecan is diarrhea (147).  Thus, the combination of 
safingol and irinotecan would exhibit non-overlapping toxicity profiles. 
Furthermore, the concentration of irinotecan could be reduced by 3.7- to 250-
fold when combined with safingol in 1:1 molar ratio. This demonstrates the 
therapeutic potential of safingol/irinotecan combination which could allow 
substantial dose reduction of irinotecan and thus minimizing the dose-limiting 
diarrhea observed with the clinical use of irinotecan (147).   
 
In summary, the current study provides supporting evidence to the 
therapeutic potential of safingol, which has been shown to act synergistically 
with a number of conventional chemotherapeutics (109, 114, 116-120, 151).  
The effectiveness and synergism of safingol/irinotecan at 1:1 molar ratio could 
be attributed to the down-regulation of the PKC pathway.  While these results 
suggest that the inhibition of PKC by the safingol/irinotecan combination is an 
attractive and effective strategy to enhance colon cancer cell killing, the 
molecular effects of safingol as a single agent require further investigation. In 
the next chapter, the focus of research is to elucidate the molecular effects of 
safingol, in particular on how it causes cancer cell death.   
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Chapter 4: The role of reactive oxygen species and autophagy 




The results presented in Chapter 3 have shown that mechanisms other 
than PKC inhibition may be involved in safingol-induced cell death, 
particularly at clinically achievable concentrations (≤ 10 µM). Two recent 
findings have shed new light on the potential molecular mechanisms of 
safingol. First, safingol could generate ROS production in fungi and plant cells 
(163, 164), yet no studies have been done in human cancer cells. It is therefore 
proposed that ROS could play a role in mediating safingol-induced cancer cell 
death. This is further supported by the observation that bioactive lipids such as 
ceramide could induce ROS production in lymphoid cells (165). Second, 
safingol was previously shown to induce autophagic features in hepatocytes of 
TRAMP mice (140) and HCT-116 cells (127). However, the role of autophagy 
in safingol-treated cells remains unclear as none of the reported studies 
determined whether the autophagic process promotes cell survival or cell 
death. Therefore, in this chapter, the role of ROS and autophagy in 
determining the fate of safingol-treated cells is elucidated. It is demonstrated 
here that ROS plays a critical role in causing cell death by necrosis in safingol-
treated cells, and autophagy is induced as a cell repair mechanism to 
counteract the damaging effect caused by ROS.  
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4.2. Results  
 
4.2.1. Safingol induced necrosis in MDA-MB-231 and HT-29 cells 
 
 
As demonstrated in Chapter 3, safingol-induced DNA fragmentation 
was observed in HT-29 and LS-174T cells, as indicated by an increase in the 
sub-G1/G0 fraction (Table 3.3 and 3.4). DNA fragmentation could be due to 
apoptosis or necrosis. Therefore, to investigate whether the increase in sub-
G1/G0 fraction was associated with apoptotic cell death, specific inhibitors to 
caspases 8 and 9 and pan-caspase inhibitor were added to safingol-treated HT-
29 and MDA-MB-231 cells. This is because apoptosis pathway involves 
caspases activation. MDA-MB-231 cells, a human breast cancer cell line, were 
also used in this study in order to test whether the molecular effect of safingol 
was cancer-type specific. In addition, breast cancer remains the most prevalent 
type of cancer in Singaporean women; thus, it would be worthwhile to 
examine the effect of safingol in a breast cancer cell line.  As seen in Figure 
4.1, pre-treatment with 50 µM of all the caspase inhibitors did not reverse cell 
death induced by safingol in MDA-MB-231 and HT-29 cells. These results 
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Figure 4.1 Caspase-independent cell death in safingol-treated MDA-MB-
231 and HT-29 cells. The effects of three caspase inhibitors, z-VAD-fmk 
(pan caspase inhibitor), z-IETDfmk (caspase 8 inhibitor) and z-LEDH-fmk 
(caspase 9 inhibitor) on the viability of safingol-treated MDA-MB-231 and 
HT-29 cells were examined. 5 µM doxorubicin was used as the positive 
control. Cells were pretreated with caspase inhibitor for 1 h before the 
addition of 2, 5 and 10 µM safingol for further 48 h. Cell viability was 
assessed using MTT. Results shown are means ±  SEM from three 
independent experiments. No statistical difference was detected.   
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In order to further understand the cytotoxicity mediated by safingol, 
flow cytometric analysis was performed after staining the cells with Annexin 
V-FITC/7AAD. Paraformaldehyde 2% was included as a positive control for 
inducing necrosis in cells. No significant increase in the percentage of cells 
stained positive for Annexin V-FITC was observed in MDA-MB-231 and HT-
29 cells after a 48-h exposure to safingol (Figure 4.2). In contrast, 
concentration-dependent increase in the percentage of cells stained positive for 
7AAD was observed (Figure 4.2), indicating a loss of cell membrane integrity 
that is suggestive of necrotic cell death. As the loss of MMP and depletion of 
ATP have been described as the hallmarks of necrosis (14, 16), measurements 
on these two biochemical events were performed. Remarkable loss of MMP in 
HT-29 cells was observed after a 48-h exposure to 10 µM safingol (Figure 
4.3). Significant depletion of cellular ATP was also observed in both cell lines 
with 10 µM safingol (Figure 4.4). Taken together, these data suggest that 
necrosis, rather than apoptosis, is the main mode through which cancer cell 
death occurred upon safingol treatment.  
 
To further examine whether the execution of necrotic cell death is a 
programmed event that involves RIP1 kinase, cells were exposed to safingol 
with or without necrostatin-1, a small molecule inhibitor of RIP1 kinase (167). 
The results indicated that necrostatin-1 did not prevent safingol-induced cell 




























































































Figure 4.2 Mode of cell death induced by safingol treatment in MDA-MB-
231 and HT-29 cells. Flow cytometric analysis of MDA-MB-231 and HT-29 
cells after 2, 5 and 10 µM safingol treatment for 48 h. 2% paraformaldehyde 
was used as a positive control to induce necrosis. Cells were harvested and 
stained with Annexin V-FITC/7AAD before analyzed by flow cytometry. 








Figure 4.3 Effect of safingol on MMP in HT-29 cells. Cells were treated 
with 10 µM safingol for 8, 24 and 48 h, stained with JC-1 and subjected to 
flow cytometry. Representative dot plots from three independent 







































Figure 4.4 Effect of safingol on intracellular ATP in MDA-MB-231 and HT-
29 cells. Cells were treated with 2, 5 and 10 µM safingol for 48 h before 
measurement of ATP by a luminometric assay. Results shown are means ± 




























































Figure 4.5 Effect of necrostatin-1 on the viability of safingol-treated MDA-
MB-231 and HT-29 cells. Cells were treated with 2, 5 and 10 µM safingol ± 
100 µM necrostatin-1 for 48 h. Cell viability was assessed using MTT assay. 
Results shown are means ± SEM from three independent experiments.  
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4.2.2. Safingol induced ROS generation in MDA-MB-231 and HT-29 
cancer cells 
 
As described in Chapter 1, overproduction of ROS has been 
documented in initiating irreversible damage to proteins, nucleic acids and 
lipids, which subsequently leads to cell death by necrosis (14, 92). In light of 
previous findings that safingol could induce ROS generation in fungi and plant 
cells but never in cancer cells (163, 164), studies were done to probe if ROS 
would be generated in cancer cells upon safingol treatment.  MDA-MB-231 
and HT-29 cells were loaded with the ROS probe, 2’,7’-
dichlorodihydrofluorescein diacetate (H2DCFDA), and H2O2 was included as 
a positive control.  As shown in Figure 4.6A and 4.6B, safingol induced ROS 
generation in a time- and concentration-dependent manner, as reflected by the 
increase in fluorescence intensity. The highest amount of ROS was generated 
after 8 h of exposure to 10 µM safingol, with ~11- and 7-fold increases over 
untreated control in MDA-MB-231 and HT-29 cells, respectively (Figure 
4.6A and 4.6B).  
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Figure 4.6 Detection of ROS by fluorescence intensity measurement using a 
microplate reader and fluorescence microscope. (A) Cells were treated with 2 
µM (●), 5 µM (▼), 10 µM (♦) safingol and 200 µM H2O2 (■) for the indicated 
time before incubation with 5 µM H2DCFDA. Fluorescence intensity was 
measured. In parallel, cell viability was monitored using WST-1. Fold increase 
in ROS production in treated cells was compared to untreated cells, and 
calculated by the equation as described in Chapter 2. Each reported value 
represents the mean ± SEM from three independent experiments (*,#p<0.05, 
compared with untreated control). (B) Cells were treated with 2, 5 and 10 µM 
safingol and H2O2 for 8 h. After incubation with 5 µM H2DCFDA, cells were 
washed and examined by fluorescence microscope. Representative images of 
cells from three independent experiments were shown. Bar = 100 µm.  
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4.2.3. ROS trigger induction of autophagy in MDA-MB-231 and HT-29 
cells 
 
Based on the results obtained in Figure 4.6A and 4.6B, it was 
postulated that autophagy would be triggered as a result of ROS generation in 
the cancer cells upon safingol treatment, as ROS could induce cellular 
damages (84-86).  As demonstrated through the ultrastructural morphology 
using transmission electron microscopy, safingol-treated MDA-MB-231 and 
HT-29 cells displayed characteristic autophagosomes, as well as cytoplasmic 
vacuoles (Figure 4.7). Concentration-dependent formation of acidic vesicular 
organelles (AVO) could be observed in safingol-treated cells when stained 
with the lysosomo-tropic agent, acridine orange (55, 168), and formation of 
AVO was markedly suppressed in both cell lines in the presence of 1 mM 3-
methyladenine (3-MA), the most commonly used autophagy inhibitor (169) 
(Figure 4.8).  Induction of autophagy is further supported by the conversion of 
LC3-I to LC3-II in a concentration- and time-dependent manner upon safingol 
treatment in the two cell lines (Figure 4.9A and 4.9B). While Atg 7 and 5 
were increased after 2 h of 10 µM safingol treatment in MDA-MB-231 cells, 
the increase in Atg 12 expression was seen after 8 h (Figure 4.9B). In HT-29 
cells, the changes in Atg protein expressions were less obvious (Figure 4.9B). 
Importantly, in the presence of the ROS scavenger, N-acetyl-L-cysteine 
(NAC), marked reduction in the formation of AVO and in the conversion of 
LC3-I to LC3-II could be demonstrated in MDA-MB-231 and HT-29 cells 





















Figure 4.7 Detection of autophagy by ultrastructural features of safingol-
treated cells. MDA-MB-231 cells were treated with 5 µM safingol while HT-
29 cells were treated with 10 µM safingol for 24 h. Cells were harvested, 
fixed and observed under transmission electron microscopy. Representative 
images of cells from three independent experiments with different 
magnification and scale bars were shown. a) control; b-d) safingol-treated 
cells. N indicates nucleus; M indicates mitochondria; arrow indicates double 









- 3-MA + 3-MA 
Figure 4.8 Detection of autophagy by AVO formation in safingol-treated cells. 
Cells were treated with safingol ± 1 mM 3-MA for 24 h before stained with 1 
µg/mL acridine orange for 15 mins. Cells were examined by fluorescence 
microscopy. Representative images of cells from three independent 
experiments were shown. Bar = 100 µm. 
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Figure 4.9 Induction of autophagic biomarkers in MDA-MB-231 and HT-
29 cells. (A) Concentration-dependent up-regulation of LC3-II after 
safingol treatment for 48 h. (B) Time-dependent up-regulation of LC3-II, 
Atg 7, Atg 5 and Atg 12 expression after 10 µM safingol treatment. Protein 
lysates were collected and assayed by Western blotting. β-actin was used as 














































Figure 4.10 ROS trigger autophagy in MDA-MB-231 and HT-29 cells. (A) 
Detection of AVO in safingol-treated cells in the presence of NAC. Cells were 
treated with safingol ± 10 mM NAC for 24 h before stained with 1 µg/mL 
acridine orange for 15 mins. Cells were examined by fluorescence microscopy. 
Representative images of cells from three independent experiments were shown. 
Bar = 100 µm. (B) Down-regulation of LC3-II in cells in the presence of NAC. 
Cells were treated with safingol ± 10 mM NAC for 48 h. Protein lysates were 
assayed by Western blotting and β-actin was used as the loading control. All 
blots shown are representative of three independent experiments.  
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Taken together, these results have demonstrated that safingol is capable of 
inducing autophagy, which are in line with two recent reports (127, 140), and 
that autophagy is induced as a result of ROS generation upon safingol 
treatment.    
 
4.2.4. The role of autophagy and ROS in response to safingol treatment  
 
Increased autophagic activity has been suggested to associate with cell 
death despite a lack of causative relationship of these two events (14).  On the 
other hand, cell death could be accelerated when autophagy is suppressed, 
suggesting a pro-survival role of autophagy (14). To assess the role of 
autophagy in safingol-induced cancer cell death, two different 
pharmacological inhibitors of autophagy, 3-MA and bafilomycin A1 (BA1), 
which act at different points of the autophagic pathway were utilized (170).  
Viability was >85% of control when the cancer cells were exposed to 3-MA or 
BA1 alone.  Suppression of autophagy by the inhibitors did not block cell 
death brought about by 2 or 5 µM safingol (Figure 4.11). On the contrary, 
significant augmentation in cell death was observed upon autophagy 
suppression. At the highest concentration of safingol tested (10 µM), the 
presence of 3-MA or BA1 did not impart any significant effect on cell 
viability (Figure 4.11).  These findings suggest that low concentrations (2 – 5 
µM) of safingol induced low levels of ROS and damage whereby the 
autophagic pathway could degrade the damaged cellular components. In 
contrast, a high concentration of safingol induced significant levels of ROS 


























































Figure 4.11 Effect of autophagy inhibitors on the viability of safingol-
treated cells. Cells were treated with safingol for 24 h before the incubation 
with 1mM 3-MA or 5 nM BA1 for additional 48 h. Cell viability was 
assessed using MTT assay. Results shown are means ± SEM from three 
independent experiments. *p<0.05, compared with untreated control.  
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To further substantiate the role ROS play in safingol-induced cancer 
cell death, the viability of MDA-MB-231 and HT-29 cells was determined in 
the presence and absence of the ROS scavenger, NAC. Indeed, upon removal 
of ROS by NAC, the percentage of safingol-treated cells stained positive for 
7AAD was significantly reduced from 86.9% to 14.6% for MDA-MB-231 and 
from 68.4% to 42.4% for HT-29 (Figure 4.12).  Taken together, these data 
indicate that ROS play an important role in mediating safingol-induced 
autophagy and necrotic cell death.  
 
4.2.5. Bcl-xL and Bax regulates safingol-induced autophagy  
 
Based on recent findings that Bcl-2 homologues regulate autophagy by 
binding directly to beclin-1, an autophagy-inducing protein that contains a 
BH3 domain (45), the involvement of Bcl-xL and Bax in safingol-induced 
autophagy was examined. While the expression of beclin-1 was slightly up-
regulated after exposure to 10 µM safingol for 48 h, a time-dependent decrease 
in Bcl-xL expression was observed in both cell lines with concomitant 
increase in Bax expression (Figure 4.13A).  This observation is expected, 
based on previous studies that showed the inhibitory role of Bcl-xL on the 
induction of autophagy (48). In the presence of the Bcl-xL inhibitor, gossypol, 
an increase in AVO formation was observed (Figure 4.13B).  Furthermore, 
the percentage of viable cells was significantly increased in the presence of 
gossypol, as reflected by an increase in EC50 values from 5.7 ± 0.79 µM (no 
















































































Figure 4.12 Flow cytometric analysis of MDA-MB-231 and HT-29 cells 
after treated with 10 µM safingol ± 10 mM NAC for 48 h. Cells were 
harvested and stained with Annexin V-FITC/7AAD before analyzed by flow 
cytometry. Representative dot plots are shown and each reported value 
represents the mean ± SEM from three independent experiments.  
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Figure 4.13 Regulation of autophagy by beclin-1, Bcl-xL and Bax in safingol-
treated MDA-MB-231 and HT-29 cells. (A) The involvement of beclin-1, Bcl-
xL and Bax in safingol-treated cells. Cells were treated with 10 µM safingol for 
the indicated time. Protein lysates were assayed by Western blotting and β-actin 
was used as the loading control. All blots shown are representative of three 
independent experiments. (B) Detection of AVO in safingol-treated cells in the 
presence of Bcl-xL inhibitor, gossypol. Cells were treated with safingol ± 5 µM 
gossypol for 24 h before stained with 1 µg/mL acridine orange for 15 mins. Cells 
were examined by fluorescence microscopy. Representative images of cells from 







































 6.4 ± 0.35 µM (no gossypol) to 8.6 ± 0.43 µM (with gossypol) in HT-29 cells 
(Figure 4.14), which is in line with the notion that less suppression on 
autophagy was present under Bcl-xL inhibition.   
 
4.2.6. Safingol reduced glucose uptake 
 
The results thus far suggest that ROS generation mediates safingol-
induced cancer cell death. It is therefore of interest to investigate how safingol 
induced ROS generation in these cells.  Previously, sphingolipids have been 
shown to inhibit glucose uptake (171, 172), which could in turn induce 
oxidative stress (173-175). These reports provided the basis to hypothesize 
that safingol, a synthetic sphingolipid, might be able to inhibit glucose uptake.  
Using a fluorescent derivative of glucose, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-
4-yl)amino)-2-deoxyglucose (2-NBDG), the uptake was probed in MDA-MB-
231 and HT-29 cells. The results showed that 10 µM safingol significantly 
inhibited 2-NBDG uptake in both cell lines as early as 2 h (Figure 4.15), 
preceding the generation of ROS (Figure 4.6).  
 
Considering the fact that AMP-activated protein kinase (AMPK) and 
mTOR are  critical energy sensors that also play a role in autophagy regulation 
(176), the effect of safingol on the phosphorylation of AMPK and mTOR was 
examined. As shown in Figure 4.16, 10 µM safingol caused a rapid and 
marked increase of AMPK phosphorylation at 2 h in both cell lines, which is 
in line with the observation that safingol inhibited glucose uptake (Figure 
4.15). A decrease in phosphorylated mTOR  was seen in HT-29 at  
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Figure 4.14 Effect of gossypol on the viability of safingol-treated cells. Cells 
were treated with safingol ± 5 µM gossypol for 24 h. Cell viability was 
assessed using MTT assay. Results shown are means ± SEM from three 
independent experiments. * compared with untreated control. 
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Figure 4.15 Effect of safingol on glucose uptake in MDA-MB-231 and 
HT-29 cells. Cells were cultured in glucose-free media for 24 h before 
treated with 10 µM safingol for the indicated time. Cells were incubated 
with a fluorescent glucose derivative, 2-NBDG, for 30 mins before 
examination by fluorescence microscopy under similar conditions. 
Representative images of cells from three independent experiments were 
















Figure 4.16 Expression levels of p-AMPK and p-mTOR in safingol-
treated MDA-MB-231 and HT-29 cells. Cells were treated with 10 µM 
safingol for the indicated time. Protein lysates were assayed by Western 
blotting and β-actin was used as the loading control. All blots shown are 
representative of three independent experiments.  
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 24 h, with minimal visible changes detected in MDA-MB-231 cells (Figure 
4.16). These results were expected as an increase in p-AMPK and a reduction 





The studies in this chapter focus on elucidating the alternative 
molecular effects of safingol in cancer cells. Here, the critical role of ROS was 
demonstrated in safingol-treated human cancer cell lines, MDA-MB-231 and 
HT-29. Interestingly, such ROS production could also trigger autophagy 
which appeared to be a repair mechanism. In addition, the current data have 
shown that glucose uptake is an event inhibited by safingol that precedes ROS 
generation. Based on these findings, a proposed model depicting the 
mechanism of safingol in MDA-MB-231 and HT-29 cells is given in Figure 
4.17. It appears that when glucose uptake into cells was disrupted, ROS were 
generated. Importantly, the ROS levels generated in the cell determine 
survival or death that is mediated through the catabolic autophagic process or 
necrosis, respectively. In addition, safingol-induced autophagy might be Bcl-
xL-, Bax-, p-AMPK- and p-mTOR-dependent.  
 
Regardless of how and where ROS are generated, a rise in ROS levels 
has two potential consequences: damage to cellular components and triggering 
various signaling pathways (65). Here, the accumulation of ROS is shown to 
be essential for safingol-induced cell death as such death can be largely 
prevented by NAC. However, in Aspergillus nidulans, Cheng et al reported 
that the fungicidal activity of safingol does not require ROS, despite a rapid 
accumulation of ROS was observed (163). Such discrepancy is likely due to 
the difference in cancer cell response compared to that of fungi. In the current 


















Figure 4.17 Proposed model depicting the mechanism of action of safingol 
in MDA-MB-231 and HT-29 cells.  
 
Abbreviations used: ROS, reactive oxygen species; NAC, N-acetyl-L-
cysteine; AMPK, AMP-activated protein kinase; mTOR, mammalian target 
of rapamycin. 
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 are the main sites of ROS production (68), are only affected after a 48-h 
exposure to safingol. This suggests that ROS could be the mediator leading to 
the loss of MMP, possibly by triggering the opening of the MPTP that 
subsequently leads to cell death. The results obtained in this chapter 
demonstrate that safingol-treated cells undergo accidental necrotic cell death, 
as reflected by the caspase-independent cell death, rupture of plasma 
membrane integrity, loss of MMP and depletion of ATP, but not the 
involvement of RIP1 kinase. By targeting a non-apoptotic cell death pathway, 
safingol might provide an alternative strategy for developing combination 
therapies, in particular to eliminate cells which are resistant to apoptotic cell 
death.  
 
In line with two previous studies (127, 140), the current results have 
demonstrated that safingol induced autophagy, possibly being regulated by 
Bcl-2 family proteins. The down-regulation of Bcl-xL and up-regulation of 
Bax observed here is consistent with the finding that arsenic trioxide induced 
autophagy in U118 human glioma cells in the absence of apoptosis, despite 
being regulated by Bcl-2 family proteins (177). Parallel with this, studies have 
illustrated the binding of Bcl-xL and Bcl-2 to beclin-1, thus preventing 
autophagy (48). On the other hand, Bax activation has been shown to induce 
autophagy which is Atg 5-, Atg 7- and Atg 10-dependent (178). In the current 
study, the subtle changes of the expression levels of Atg proteins could be 
because ROS affects Atg 4 (84), which is yet to be determined. Though 
safingol-induced autophagy has been clearly demonstrated, it is yet to unveil 
whether the autophagic process directly contributes to death or is merely a 
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catabolic process to preserve cell viability. The current data suggest the latter, 
where autophagy functions possibly as a mechanism to remove damaged 
organelles and proteins in response to safingol-induced oxidative stress. 
Additional studies such as measuring the lipid or protein peroxidation could be 
performed in the future to confirm oxidative damage. Besides supporting the 
current knowledge that ROS regulates autophagy (84, 86), these data are also 
in line with findings that sphingolipids-induced autophagy was shown to have 
a protective role towards cell death, especially during nutrient starvation (179).  
 
The current results offer an explanation that glucose uptake inhibition, 
resulting in an increase in AMPK phosphorylation, could be one of the factors 
leading to ROS generation. Consistent with this study, glucose deprivation in 
lung cancer cells A549 (180), brain cells (174, 175), retina cells (181) and 
adrenal cells (182) was shown to initiate oxidative stress and increase 
mitochondria production of ROS. Though controversial, AMPK is not only 
known as an energy sensor, but also reported to play a role in inducing 
autophagy through the suppression of mTOR (176). However, compared to 
ROS generation, the direct effect of AMPK and mTOR on safingol-induced 
autophagy warrants further studies. The addition of pharmacological activators 
and inhibitors of AMPK and mTOR could be explored in safingol-treated cells.  
 
In summary, the current studies provide experimental evidence that 
ROS play a key role in mediating the cytotoxicity of safingol in cancer cells. It 
is worthwhile to note that depending on the magnitude and the duration of 
exposure, ROS can elicit different responses. Safingol at 2 and 5 µM resulted 
 111 
in low levels of ROS production, and autophagy was possibly induced to 
remove oxidatively-damaged organelles. However, at 10 µM safingol 
treatment, high levels of ROS were produced and exceeded the cells’ repair 
capacity, thus, leading to cell death by necrosis. Together, these data suggest 
that safingol may be an attractive agent to combine with apoptotic- and ROS-
generating anti-cancer drugs at appropriate concentrations to treat potential 
drug-resistant cancers. It is anticipated that such combinations of drugs may 
show synergistic effect by executing different modes of cell death. Therefore, 
the focus of the next chapter was to investigate the effects of safingol in 
combination with apoptotic- and ROS-generating chemotherapeutic agents.  
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Chapter 5: Synergistic cytotoxic effect of safingol and 
conventional chemotherapeutic agents   
 
5.1. Introduction  
 
 
As described in Chapter 1, combination therapies have been the 
cornerstone of cancer therapy in clinical practice. However, current 
therapeutic strategies still face significant challenges owing to acquired drug 
resistance, particularly to apoptotic-inducing chemotherapies. Statistically, 
more than 50% of cancers are reported to have defects in the apoptotic 
machinery (15). These resistant cancer cells, however, remain susceptible to 
non-apoptotic death. In such a scenario, agents that target alternative cell death 
pathways would be therapeutically useful.  
 
Previous studies have shown that cancer cells are under increased 
oxidative stress compared to normal cells (183, 184). Such oxidative stress is 
due to the overproduction of ROS. This intrinsic oxidative stress of cancer 
cells render them particularly vulnerable to ROS insults as ROS are 
chemically active and can inflict cellular damage (183, 184). Therefore, 
manipulating ROS levels could be a way to kill cancer cells selectively (185). 
A few strategies have been proposed, including direct ROS generation, 
glutathione depletion, and anti-oxidant enzyme inhibition as reviewed by 
Pelicano et al (185).  
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Having demonstrated in the previous chapters in this thesis, the 
mechanisms of safingol-induced cell death are complex, and probably involve 
several pathways including inhibition of SK, PKC as well as inducing 
oxidative stress through the generation of ROS as shown in Chapter 4. 
Furthermore, safingol was demonstrated to synergize with various 
chemotherapeutic agents in a variety of cancer cell lines. Together, these 
observations provided the basis to hypothesize that combining safingol with 
agents that generate ROS production may provide an alternative strategy to 
eliminate cancer cells.  
 
In this chapter, safingol was proposed to combine with four anti-cancer 
drugs which belong to different classes of conventional chemotherapies. These 
include carboplatin, doxorubicin, gemcitabine and vincristine. There are two 
main reasons for selecting these drugs. First, the selected conventional 
chemotherapeutic agents induce primarily apoptotic cell death, which was 
expected to compliment the activity of safingol-induced necrosis. Second, 
these drugs are reported to generate ROS. Carboplatin is the second generation 
of platinum compounds that binds to DNA and induces DNA cross-linkage. 
Carboplatin has been shown to induce oxidative stress-associated apoptosis in 
rats and cardiac myocytes (186, 187). Doxorubicin, belongs to the class of 
anthracycline, is a topoisomerase II inhibitor. Doxorubicin intercalates DNA 
and generates reactive oxygen species (188). Gemcitabine is a nucleoside 
analog that interferes with the DNA replication by replacing cytidine. Though 
the precise mechanism remained to be defined, gemcitabine was reported to 
generate free radicals and induce mitochondria injury (189, 190). Vincristine, 
 114 
a natural vinca alkaloid, is known to bind irreversibly to microtubules and 
spindle proteins. Likewise, the cytotoxic effect of vincristine has been 
suggested to be linked to the generation of ROS (191).   
 
Previously, although safingol was reported to enhance the cytotoxic 
effect of other chemotherapeutic agents, no quantitative measure of synergism 
was demonstrated, except for one study which combined safingol with 
fenretinide (119). Furthermore, as discussed earlier, the ratios of individual 
agents comprising the drug combinations could significantly influence the 
therapeutic outcome. Therefore, in this study, drug combinations consisted of 
safingol with carboplatin, doxorubicin, gemcitabine and vincristine at 1:4 and 
4:1 fixed molar ratios were evaluated in a variety of human cancer cell lines 
covering both hematological and solid malignancies. The pharmacological 
interaction between safingol and the anti-cancer drugs were properly evaluated 
using the median effect principle described by Chou and Talalay (10).   
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5.2. Results  
 
5.2.1. Effect of safingol as a single agent in human cancer cell lines 
 
  The biological effect of safingol on various human cancer cell lines 
was examined. Cell viability was determined using MTT assay.  After safingol 
exposure of 72 h, the viability of cancer cells was reduced by safingol in a 
concentration-dependent manner (Figure 5.1). As shown in Table 5.1, 
safingol was most potent in SKOV-3, an ovarian cancer cell line, with an IC50 
value of 1.4 ± 0.18 µM. The IC50 values of safingol in breast, ovarian, 
leukemic and nasopharynx cancer cell lines are within the same molar of 
magnitude, ranging from 1.4-6.3 µM. Of note, these IC50 values of safingol 
could be achieved in the bloodstream according to a pilot Phase I study (114). 
Compared to doxorubicin, gemcitabine or vincristine, safingol was less potent 
in the respective cell lines tested (Table 5.1). Interestingly, safingol was more 
potent than carboplatin in KB cell line, with ~ 7.9-fold higher in potency 
(Table 5.1).  
 
5.2.2. Effect of fixed ratio combinations of safingol and conventional 
chemotherapeutic agents  
 
Next, 1:4 and 4:1 fixed molar ratio combinations of safingol and 
chemotherapeutic agents were evaluated over a range of concentrations. The 
measure of synergy between safingol and the cytotoxic drugs was determined 




































































































Figure 5.1 Effect of safingol treatment on the viability of different cancer cell 
lines. Cells were treated with safingol for 72 h. Cellular viability was assessed 

















4.4 ± 1.0 0.71 ± 0.15* 0.22 ± 0.08* - - 
JIMT-1 2.8 ± 0.45 0.43 ± 0.07* 0.07 ± 0.03* - - 
SKOV-3 1.4 ± 0.18 0.60 ± 0.14 0.20 ± 0.12* - - 
KB 6.3 ± 1.3 - - 50 ± 7.1* - 
U937 2.4 ± 0.1 - - - 0.0011 ±  
0.00027* 
Table 5.1 IC50 values of safingol and conventional anti-cancer drugs in 
respective cancer cell lines. 
Cell viability was determined using MTT assay and subsequently analyzed by Calcusyn 3.0 
software to estimate IC50 values. Each reported value is the mean ±  SEM from three 
independent experiments. All r values were ≥ 0.9. *p<0.05, significantly different from safingol-
treated group.  
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and Talalay (10). The CI values and dose reductions were estimated at an 
effect level of 90% cell kill for the various ratios and were summarized in 
Table 5.2 and Figure 5.2, respectively. Three important observations could be 
made. First, a ratio-dependent CI profile was observed (Table 5.2). 
Interestingly, 4:1 molar ratio of safingol with carboplatin, doxorubicin, 
gemcitabine and vincristine consistently provided synergy in the respective 
cell lines (Table 5.2). Among these safingol-based combinations, 
safingol/gemcitabine (4:1) combination showed strongest synergism, with a CI 
value of 0.07 achieved in SKOV-3 cells (Table 5.2). On the other hand, 
safingol/gemcitabine at 1:4 molar ratio showed antagonism in MDA-MB-231 
and JIMT-1, as shown by CI values > 1 (Table 5.2). These results were in line 
with the notion that the treatment outcome of drug combinations could be 
highly dependent on the molar ratios of the individual agents (9). Second, 
substantial dose reduction of safingol and chemotherapeutic agents was 
achieved when used in combination as compared to the administration of 
individual agents (Figure 5.2). In particular, when safingol and gemcitabine 
were used at 4:1 molar ratio, the concentrations to achieve 90% cell kill in 
SKOV-3 cells for safingol and gemcitabine were reduced by 2.0-fold and 
3428-fold, respectively (Figure 5.2). Third, safingol was able to act 
synergistically with different classes of chemotherapeutic agents (Table 5.2). 
This is therapeutically beneficial to provide an alternative treatment approach 










Safingol + Cell line Molar ratio 
of saf/drug 
CI90 r Interaction 
Alkylating agent      
Carboplatin KB 1:4 0.96 0.96 Additive 
  4:1 0.77 0.98 Synergistic 
Anthracycline       
Doxorubicin  MDA-MB-231 1:4 0.56 0.90 Synergistic 
  4:1 0.28 0.84 Synergistic 
 JIMT-1 1:4 0.46 0.96 Synergistic 
  4:1 0.42 0.84 Synergistic 
 SKOV-3 1:4 0.44 0.98 Synergistic 
  4:1 0.61 0.92 Synergistic 
Antimetabolite       
Gemcitabine  MDA-MB-231 1:4 2.1 0.99 Antagonistic 
  4:1 0.55 0.97 Synergistic 
 JIMT-1 1:4 1.4 0.93 Antagonistic 
  4:1 0.49 0.95 Synergistic 
 SKOV-3 1:4 1.0 0.90 Additive 
  4:1 0.07 0.95 Synergistic 
Vinca alkaloids       
Vincristine  U937 1:4 0.39 0.90 Synergistic 
  4:1 0.24 0.94 Synergistic 
Table 5.2 Combination indices of safingol with different classes of anti-cancer 
drugs in respective cancer cell lines  
Results from MTT viability assay were pooled from three independent studies and used to 
compute the CI values using Calcusyn 3.0 software. The reported CI values were based on the 
drug concentration to achieve 90% cell kill. CI <1, ~1 or >1 denotes a synergistic, additive or 
antagonistic interaction of the combination, respectively. r represents the linear correlation 


























































































Figure 5.2 Dose reduction analysis of safingol-based drug combinations. The 
drug concentrations required to achieve 90% cell kill of safingol (clear bars) and 
respective anti-cancer drugs (filled bars) used alone or at 1:4 and 4:1fixed molar 
ratio are shown. Carb represents carboplatin; Dox represents doxorubicin; Gem 




























































































5.2.3. Effect of fixed ratio combinations of safingol and conventional 
chemotherapeutic agents in the presence of NAC  
 
To verify whether ROS generation was responsible for the synergism 
observed, safingol/carboplatin (4:1) in KB, safingol/doxubicin (4:1) in MDA-
MB-231, safingol/gemcitabine (4:1) in SKOV-3 and safingol/vincristine (4:1) 
in U937 cells were further evaluated with the addition of NAC.  These drug 
combinations were selected as they demonstrated the most promising results 
that are reflected by their CI values in the respective classes of anti-cancer 
drugs (Table 5.2). As expected, the percentage of viable cells was increased 
when ROS were removed by NAC in all the safingol-based combinations 
(Figure 5.3), and this improvement in cell viability could be achieved when 
the concentration of safingol was 5-10 µM used in combinations with other 
anti-cancer drugs (Figure 5.3). These results, thus, suggest that ROS may play 

























  Figure 5.3 Effect of NAC on safingol-based drug combinations observed in a 
panel of cancer cell lines. MDA-MB-231 cells were treated with 
safingol/doxorubicin (4:1) ± 10 mM NAC, SKOV-3 cells were treated with 
safingol/gemcitabine (4:1) ± 10mM NAC, KB cells were treated with 
safingol/carboplatin (4:1) ± 10 mM NAC and U937 cells were treated with 
safingol/vincristine (4:1) ± 5 mM NAC. All cells were treated for 48 h and cellular 
viability was assessed using MTT assay. The results shown are the viability of 
cells when safingol concentration was 5 µM in all cell lines, except for KB cells 
which were exposed to 10 µM safingol. Results shown are means ± SEM from 
three independent experiments. * NAC-treated group compared to no NAC group. 
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To date, the mainstay of cancer therapy is drug combination. Majority 
of the previous studies in literature were done to combine safingol with 
various anti-cancer drugs at one specific concentration. However, this 
approach does not take into account that the treatment outcome often depends 
on the concentration and the ratio of the combined drugs (9). Therefore, in this 
study, fixed molar ratios of safingol in combination with other anti-cancer 
drugs were used. It is demonstrated that safingol in combination with 
carboplatin, doxorubicin, gemcitabine and vincristine could act synergistically 
in killing a variety of cancer cells at specific drug molar ratios, and such 
synergism could possibly be mediated by ROS.  
 
Increased ROS levels have long been observed in cancer cells (183, 
184), and several mechanisms have been proposed to contribute to the 
increased ROS levels in cancer cells. These include the signals from 
oncogenes such as c-myc and ras (192), which produce ROS through NADPH 
oxidase to proliferate (193). Another mechanism by which cancer cells 
increased ROS could be due to the mutations in mitochondrial DNA, and this 
correlation has been shown in primary leukemia cells (194). Recent studies 
suggest that this characteristic of cancer cells can be exploited for therapeutic 
benefits. This is because compared to the normal cells, cancer cells would be 
more dependent on anti-oxidant systems to cope with oxidative stress. Thus, 
additional exogenous ROS, either caused by ROS-generating agents or anti-
oxidant inhibitors, would trigger more ROS damage in cancer cells (185, 195). 
 124 
In the current study, the conventional anti-cancer drugs used have been shown 
to increase ROS production (186-191). Furthermore, in line with the previous 
findings that safingol induced ROS production, sphingolipids such as C2- and 
C6-ceramides were shown to cause a rise in mitochondrial peroxide production, 
thus leading to growth arrest in U937 and apoptosis in Jurkat cells (196). 
Therefore, combining two ROS-generating agents could enhance their effect.  
  
While the results suggested that ROS could be one of the important 
mediators in the observed synergism, it is important to note that cell death was 
not completely reversed in the presence of NAC. Therefore, these data could 
not exclude that other potential mediators might contribute to the synergism 
and future studies are warranted. In conclusion, the results show that safingol 
synergize with anti-cancer drugs, possibly by inducing ROS insults that trigger 
cancer cell death.  
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Chapter 6: Summarizing discussion  
 
The sphingolipid field has emerged and gained significant attention 
over the past decades due to their roles in diverse cellular responses such as 
proliferation, inflammation, differentiation and cell death in cancer.  Multiple 
lines of evidence have revealed that safingol, a member of sphingolipid family, 
not only showed efficacy when used as a single agent, but could also synergize 
with other anti-cancer drugs. More importantly, safingol has already been used 
under phase I clinical trials without dose-limiting toxicities. Although the 
mechanisms by which safingol mediates its effects are not fully understood, 
studies designed to understand the involvement of safingol in these responses 
have begun to reveal many opportunities for exploiting sphingolipids such as 
safingol in order to achieve specific therapeutic objectives.   
 
Understanding the mode of cell death induced by anti-cancer drugs is 
no doubt important in the identification of novel anti-cancer therapies and 
therapeutic agents. The work presented in this thesis comprised of a series of 
experiments designed to address several important information gaps with the 
use of safingol in cancer research. In particular, the current work involved the 
elucidation of the mechanisms of safingol and its potential in synergizing with 
other anti-cancer drugs.  
 
Summarizing the results obtained from Chapter 3 to 5, three key points 
could be made. First, despite being known as a PKC inhibitor, 10 µM of 
safingol did not inhibit PKC, thus suggesting that other molecular effects 
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could be exerted by safingol. In contrast, when safingol was used in 
combination with irinotecan, inhibition of PKC pathway was shown to be, at 
least in part, responsible for the observed synergistic cells killing effect. 
Second, ROS appeared to be the critical mediators of safingol-induced 
necrosis as well as autophagy. The damaging effect of ROS was dependent on 
its exposure. The results shown in Chapter 4 suggest that autophagy was 
triggered in response to overcome the ROS-damaging effect and it was not a 
cell death mechanism in this study. Third, safingol could act synergistically 
with various apoptotic-inducing and ROS-generating chemotherapeutic agents, 
including carboplatin, doxorubicin, gemcitabine and vincristine, in a variety of 
human cancer cell lines. The observed synergism was shown to be partly 
attributed to ROS generation.  
 
Thus far, the studies in this thesis have proposed two possible 
mechanisms for the synergisms seen in safingol-based drug combinations. 
They are the inhibition of PKC and the involvement of ROS. As ROS and 
PKC are clearly linked to cellular signaling events in general, it is not 
surprising that there is significant interaction between ROS- and PKC-
mediated biological responses. PKC activation has been shown to up-regulate 
anti-oxidant enzyme SOD to prevent the accumulation of ROS (180). 
Remarkably, ROS generation could in turn activate PKC (83). In the studies 
presented in this thesis, it is possible that PKC pathway and ROS are working 
in parallel and the possibility for amplification of cell death should be 
considered and further investigated in the future.  
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While safingol-based anti-cancer therapies showed enhanced cell 
killing effect in a variety of cancer cells, several challenges with the use of 
safingol-based drug combinations remain. The first challenge is the selectivity 
issue of safingol. Ideally, anti-cancer drugs should be selective to cancer cells 
to ensure effective therapeutic outcome and low toxicity. Previously, Morales 
et al demonstrated that safingol could kill mice BALB 3T3 cells with an IC50 
value of 4 µM at 24 h (140). In view of this finding, the effect of safingol was 
further tested in normal lung fibroblast MRC-5 cells (Figure 6.1). Consistent 
with the study of Morales et al, safingol reduced the viability of MRC-5 cells 
in a concentration-dependent manner, and with an IC50 value of 3 ± 0.4 µM at 
72 h. The potency of safingol in MRC-5 is comparable to its killing effect in 
cancer cells. These studies, thus, suggest that safingol is not selective for 
cancer cells.  
 
  The second challenge with the use of safingol is its inherent poor 
solubility. On the basis of the encouraging in vitro results presented in Chapter 
3 to 5, it would be important to translate these results into in vivo anti-cancer 
activity in the future. However, administrating safingol in vivo could be a 
struggle. Thus far, only two different ways to administer safingol have been 
reported. When feeding to mice, Morales et al mixed powdered safingol to the 
diet of the mice (140).  Another approach reported is by preparing safingol in 
a lipid emulsion formulation (114, 122). However, safingol administered in 
emulsion was reported to induce intravascular hemolysis as the major side 
effect (114, 122).  
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Figure 6.1 Effect of safingol treatment on the viability of normal lung 
fibroblast MRC-5 cells. Cells were treated with safingol for 72 h. Cellular 
viability was assessed using MTT assay. Results shown are means ± SEM 
from three independent experiments. 
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The third challenge is to maintain the synergistic drug ratios of 
safingol-based anti-cancer therapies in tumor site. The results from Chapter 3 
and 5 have demonstrated that the effectiveness of combination therapy is 
dependent on the drug ratios and concentration. The results in this thesis were 
obtained using in vitro systems where drug concentrations could be tightly 
controlled in cancer cell lines. However, it should be noted that individual 
chemotherapeutic agents would have distinct pharmacokinetic properties when 
they are being administered in vivo. Therefore, it is important to note that the 
failure to control drug ratios in the application of drug combinations in vivo 
could lead to the exposure of cancer cells to antagonistic drug ratios, leading 
to undesirable effects such as a loss of therapeutic activity and the 
development of drug resistance (197).   
 
One potential solution to the aforementioned challenges is to employ 
drug delivery system for safingol. In this context, three main criteria in 
selecting appropriate drug delivery systems should be considered. First, a 
delivery system which could potentially reduce the side effects of safingol 
would be of great therapeutic advantage. Preferably, the delivery of safingol 
could be targeted to the tumor site. Due to the leaky vasculature and poor 
lymphatic drainage at tumor site, nanoscale (20-200 nm diameter) drug 
delivery systems are known to display selective accumulation at tumor site 
(198). Second, a delivery system which can co-deliver safingol with other 
anti-cancer drugs should be considered. As safingol is amphipathic, the 
delivery system used should be able to encapsulate both hydrophobic and 
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hydrophilic agents. Third, the synergistic drug ratios of safingol and anti-
cancer drugs should be maintained at tumor sites to obtain the desirable 
therapeutic effect. An easy approach is to formulate safingol and other anti-
cancer drug into a separate delivery system and combine the two formulated 
drugs at the synergistic ratio. However, in this scenario, the drug release rates 
and biodistribution for the encapsulated safingol and other anti-cancer drugs 
must be identical to maintain the synergistic drug ratio. These concerns can be 
resolved by encapsulating safingol and anti-cancer drugs into a single delivery 
system. Though such delivery system presents added complexity in terms of 
formulations, it has the advantage to coordinate the release of safingol and 
anti-cancer drugs. Recently, the use of drug delivery systems such as 
liposomes or polymeric nanoparticles could co-deliver and maintain 
synergistic drug ratios of therapeutic agents at the tumor site (9).  Improved 
therapeutic efficacy could be achieved through such sophisticated 
formulations in animal models, and Phase I/II clinical trials have begun to 
evaluate these novel formulations (199, 200). 
 
In summary, the work presented in this thesis elucidated the molecular 
mechanism of safingol and revealed insights on the development of novel 
strategies for combating cancer. This study also provided additional 
understanding for the on-going Phase I clinical trial which uses safingol (115). 
Given the ability of safingol to induce necrosis by generating ROS, it is 
anticipated that future developments in the field of safingol-based therapeutics 
will facilitate scientists and clinicians to tailor various therapies to trigger 
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